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ABSTRACT 
Background  
Adverse Drug Reactions (ADRs) contribute to potentially expensive hospital admissions and  are 
regarded as a major public health priority. ADRs in South Africa are mainly detected by a 
spontaneous reporting system but it is plagued by under-reporting. Previous records indicated 
under-reporting of ADRs in the Cape Winelands District amongst healthcare workers.  
Pharmacists, in particular, did not report ADRs compared to other healthcare cadres whilst they 
are generally considered to be the custodians of medicines.  
Study Aim 
This study aimed to explore and describe the perceptions and experiences of rural public sector 
pharmacists’ reporting of ADRs and to understand why pharmacists in this rural health district 
under-reported ADRs.  
Study Design 
A qualitative study design was appropriate for this research question as the researcher wanted to 
gain an in-depth understanding of human behavior related to the phenomena of under-reporting. 
Study Population and Sampling 
The primary study population consisted of 24 public sector pharmacists in the Cape Winelands 
District. A purposive sampling strategy enabled the selection of 16 pharmacists ranging in 
gender, age, experience and rank. Eight pharmacists were supervisor pharmacists while the rest 
were production pharmacists, including a community service pharmacist and an intern 
pharmacist. Supervisor pharmacists are more involved with managerial tasks and the attendance 
of meetings compared to production pharmacists that focus on patient care and dispensing of 
medication. Two key informants involved in the Western Cape Pharmacovigilance System were 
included in the study.  
 
One key stakeholder was a policy specialist pharmacist working at Directorate: Pharmacy 
Services and primarily involved with the Provincial Pharmacy and Therapeutics Committee. The 
other key policy stakeholder, at the time of the study, was the manager of the Medicines 
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Information Centre which forms part of the University of Cape Town’s (UCT) Pharmacology 
Division. Both were highly experienced pharmacists familiar with the pharmacovigilance 
system. 
Data Collection 
In-depth interviews were conducted using a semi-structured interview guide consisting of open-
ended questions. The semi-structured interview guide was tested on a participant outside the 
primary study population. Interviews were conducted in English and Afrikaans. Interviews were 
tape-recorded and the interviewers made field notes to supplement the data recorded. Two 
researchers with experience in qualitative data collection, briefed by the investigator, interviewed 
the pharmacists who worked in the district and the investigator interviewed the two key 
stakeholders. 
Data Analysis 
The tape recordings were translated, where applicable, and all were transcribed verbatim by the 
investigator. The transcribed recordings were analyzed by the investigator by assigning codes to 
material on an Excel spreadsheet. This approach enabled the identification of themes which 
aided the understanding of the research phenomena. 
Ethics 
Ethical approval was obtained from the University of the Western Cape Senate Research 
Committee and permission from the Western Cape Department of Health Research Committee. 
Written informed consent (See Appendix 1, page 73) was obtained from each participant prior to 
conducting the interviews and interviewees were assured of confidentiality throughout the 
research. 
 
Key Results and Discussion 
Pharmacists in the study strongly acknowledged the importance of ADR reporting which is 
linked with pharmacists seeing themselves as the custodians of medication. Pharmacists in the 
study associated the reporting of ADRs with medication safety and felt responsible for ensuring 
it. In spite of this acknowledgement of the importance of ADR reporting, pharmacists rarely 
reported an ADR themselves. This finding was in line with previous research conducted and 
linked with barriers pharmacists faced in practice. 
 
 
 
 
iv 
 
 
The study revealed that pharmacists identified ADR reporting opportunities during their normal 
clinical work and enabled other health care professionals (HCPs) to confirm the occurrence of an 
ADR and report it.  Pharmacists primarily identified ADRs when they scanned patient folders for 
clues that could indicate that an ADR had occurred. Other research conducted confirmed that the 
use of patient records could be used in the identification of ADRs. This finding was important to 
inform future training workshops to promote reporting of ADRs. 
 
Some pharmacists in the study associated an ADR with a therapeutic or clinical intervention. In 
general, therapeutic interventions usually involved a clinical action more closely associated with 
medical officers and were viewed by pharmacists in the study as being outside their legal and 
clinical scope of practice. A clinical intervention could include a change of medication, change 
of dose, and other prescription changes or might involve the medical officer referring the patient 
to a higher level of care depending on the severity of the suspected ADR experienced. A clinical 
intervention could include performing complex diagnostic tests, observations and laboratory 
investigations. Pharmacists’ association of an ADR experience with a clinical intervention was 
an important factor limiting their reporting of ADRs. The implication of this belief is that 
patients were referred from the pharmacy back to medical officers for the clinical intervention. In 
this way, although pharmacists do not directly report an ADR, their referral to medical officers 
would help improve reporting of ADRs.  
 
An unexpected and contrasting finding compared to previous research was the strong belief of 
some pharmacists in this study that common ADRs should be reported. Pharmacists believed that 
by reporting common ADRs en masse, authorities might decide to remove the problematic 
medication from the approved public sector formulary. This was in contrast to previous research 
where pharmacists either acknowledged that authorities only want novel or serious ADRs from 
newly marketed medication or believed that reporting well-known ADRs was a waste of time. 
 
Pharmacists reported that they faced several barriers in reporting ADRs. The main barriers that 
were mentioned were a lack of adequate feedback, heavy workload and time constraints, 
uncertainty in identifying the cause of an ADR and issues pharmacists had with the reporting 
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process. These barriers were consistent with previous research conducted. 
 
Finally, pharmacists suggested various means of facilitating ADR reporting including use of 
electronic reporting aids, creating increased awareness amongst healthcare professionals, 
conducting continuous training and making amendments to the reporting form, some of which 
were in line with previous research conducted. 
Conclusion 
Exploring the perceptions and experiences of pharmacists with respect to the under-reporting of 
ADRs revealed key knowledge about the spontaneous reporting system that could be applied to 
strengthen the current reporting system and enable more reporting. Whilst it was clear that 
pharmacists play an important role as the gatekeepers and drivers of the reporting process 
enabling other HCPs to report ADRs, more should be done to empower pharmacists in managing 
ADR reporting opportunities. This could benefit the healthcare system in ensuring that more 
ADRs are reported, as well as decrease the waiting time of patients and the workload of medical 
officers. In addition, engaging with pharmacists and HCPs to overcome barriers to reporting 
would facilitate increased ADR reporting.  
Recommendations 
Several recommendations emerged from the study. Future circulars, training workshops and 
awareness posters about the ADR reporting process should inform all HCPs to report any 
medication suspected of being the cause of an ADR and not waste time in trying to identify the 
medication that caused it. A training workshop should be conducted with pharmacists to improve 
their skills in terms of identifying ADRs, how and what to report and of the appropriate referral 
of patients to the medical officers. An annual assessment on the availability of reporting forms in 
all health facilities should be conducted. In addition, the MIC should conduct a survey on the 
user-friendliness of the reporting form and enable HCPs to provide recommendations to help 
improve the reporting form template. Pharmacovigilance should be a standing item on the 
agendas of sub-district PTC meetings at which supervisor pharmacists should give quarterly 
updates to sub-district management on ADRs reported. As this study focused primarily on the 
experiences and perceptions of pharmacists in a rural health district, a follow-up study should 
explore perceptions and knowledge of medical officers and nurses of ADR reporting, specifically 
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on the availability and complexity of the reporting form. Finally, the MIC should explore the 
development of a basic ADR causality assessment tool that could assist pharmacists and other 
HCPs in identifying a possible ADR and improve confidence amongst pharmacists and HCPs in 
reporting ADRs.  
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DEFINITIONS OF KEY TERMS 
 
Community Day Centre- a healthcare facility where healthcare services are provided by 
clinical nurse practitioners (CNPs), with the support of full-time medical officers and 
pharmacists and where patients have access to X-ray services. A CDC normally provides 
a service between 08h00 and 16h00. 
Community service pharmacist- pharmacist restricted to work only in the public sector 
at designated sites, after successful completion of an internship. 
Intern- pharmacist category post university qualification with a limited scope of practice, 
supervised by another designated, registered pharmacist called a tutor. 
Pharmacovigilance - Pharmacovigilance (PV) is defined as the science and activities 
relating to the detection, assessment, understanding and prevention of adverse effects or 
any other drug-related problem. (WHO, 2008) 
Poly-pharmacy- the practice of prescribing multiple medications to patients suffering 
from more than one illness, at the same time. 
Production pharmacist – a person who is professionally qualified to prepare and 
dispense medicinal drugs with a scope of practice prescribed in terms of Section 35A of 
the Pharmacy Act 53 of 1974. 
Responsible pharmacist- is a pharmacist who is responsible to the South African 
Pharmacy Council for complying with all the provisions of the Pharmacy Act and other 
legislation applicable to services that specially pertain to the scope of practice of a 
pharmacist and legislation applicable to the pharmacy that is under his or her personal 
supervision. 
Spontaneous Reporting- a reporting system based on voluntary reporting as opposed to 
forced reporting, where healthcare workers are forced to report ADRs. 
Supervisor pharmacist- a category of pharmacist in the public sector managing other 
pharmaceutical staff and registered as the responsible pharmacist with the South African 
Pharmacy Council. 
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CHAPTER 1: INTRODUCTION 
 
1.1. Introduction 
 
According to the World Health Organization (WHO) definition, an Adverse Drug Reaction 
(ADR) is any noxious, unintended and undesired effect of a drug, which occurs at doses used in 
humans for prophylaxis, diagnosis, or therapy (Abdel-Latif & Abdel-Wahab, 2015; WHO, 
2008). ADRs contribute to potentially expensive hospital admissions of affected patients 
(Zolezzi & Parsotam, 2005; Abdel-Latif & Abdel-Wahab, 2015). ADRs have been reported to be 
associated with a prolonged length of hospital stay, which leads to higher healthcare costs 
(Abdel-Latif & Abdel-Wahab, 2015; Doherty, 2009; Zolezzi & Parsotam, 2005). Furthermore, 
ADRs have a detrimental effect on a country’s economy due to loss of the working population’s 
income and loss of production days (Zolezzi & Parsotam, 2005).  As most ADRs can be 
considered as preventable, it is thus essential that any healthcare system needs to incorporate an 
effective and adequate pharmacovigilance management programme (Jose et al., 2014). 
Pharmacovigilance is defined as the science and activities related to the detection, assessment, 
understanding and prevention of Adverse Drug Reactions (ADRs) and drug-related problems 
(Abdel-Latif & Abdel-Wahab, 2015; WHO, 2008). 
 
 
Pharmaceutical companies are required by law in all countries to test their medications on 
healthy and patient volunteers before making them available to the general public (WHO, 2008). 
All registered medicines first have to undergo pre-clinical studies and pre-marketing clinical 
trials to ensure that they comply with international safety standards (Suleman, 2010). A clinical 
trial is any research study that prospectively assigns human participants or groups of humans to 
any health-related interventions to evaluate the effects on certain health outcomes (WHO, 2012). 
Clinical trials that are conducted under controlled conditions cannot test for all possible ADRs 
under real-world conditions as experienced by the diverse, greater population (Sarker et al., 
2015; Suleman, 2010).  Pregnant women, children and patients affected by co-morbid conditions, 
patients on multiple drug therapy and patients with decreased renal and hepatic function are often 
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not included in clinical trials. (Suleman, 2010)  After the medication has been registered and is 
commercially available, the exclusion criteria applied during clinical trials no longer exist to 
prevent potentially at-risk patients from being exposed to it during extended therapy (Zolezzi & 
Parsotam, 2005). This increases the possibility of previously undetected ADRs to surface and 
create detrimental effects on quality of life (Zolezzi & Parsotam, 2005). ADRs may also occur at 
a very low frequency, which will make it difficult to detect them in clinical trials due to the 
relatively small numbers of patients included in them (Zolezzi & Parsotam, 2005). 
 
WHO initiated an international programme for monitoring the safety of medicines in 1968 
(Oreagba et al., 2010). The programme is coordinated by the Uppsala Monitoring Centre located 
in Sweden (Oreagba et al., 2010). The Uppsala Monitoring Centre regularly publishes an 
overview of how the various national reporting systems are functioning (Van Grootheest et al, 
2004). Most pharmacovigilance programmes around the world rely on spontaneous reporting of 
ADRs from healthcare professionals (Pal et al., 2013; Green et al., 2001). Only a small number 
of African countries, including South Africa, have formal pharmacovigilance systems in place 
(Sevene et al, 2008).   These spontaneous reporting systems (SRS) play an important role in 
identifying ADRs efficiently and effectively (John et al., 2012; Palaian et al., 2011; Green et al., 
2001).  Spontaneous reporting systems have been associated with the phenomenon of under-
reporting of ADRs (Molokhia, 2009; Zolezzi & Parsotam, 2005). 
 
The Medicines Control Council (MCC), the drug regulatory authority in South Africa, oversees 
and governs pharmacovigilance in accordance with the Medicines and Related Substances 
Control Act, Act 101 of 1965 ( Act 90) as amended (Maigetter et al., 2015). The MCC has the 
responsibility to ensure the safety, efficacy and quality of all medicines in South Africa (Mehta, 
2011). The pharmacovigilance programme of the MCC is coordinated by the National 
Pharmacovigilance Centre (NPC), which is based in Pretoria (Mehta, 2011). The NPC oversees 
the National Adverse Drug Monitoring Centre (NADMC), which is based at the University of 
Cape Town (Maigetter et al., 2015; Mehta, 2011). The NADMC is responsible for the collation 
of ADR information, the management of the national ADR database and the assessment of ADR 
related risks and causality trends (Maigetter et al., 2015; Mehta, 2011).  The Medicines 
Information Centre (MIC), which is also based at the University of Cape Town, collects only 
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spontaneous ADRs from anti-retroviral medication, which are also forwarded to the NADMC 
(Maigetter et al., 2015). 
 
The NADMC is required to report ADR information to the MCC and the Uppsala Monitoring 
Centre (UMC) (Maigetter et al., 2015). Information from the national ADR database is routinely 
forwarded to the international ADR database maintained by the UMC (Mehta, 2011). The 
MCC’s pharmacovigilance committee, which consists of a pharmacist and six external 
pharmacovigilance experts, advises the MCC on the prevention and minimizing of ADR risks 
(Maigetter et al., 2015; Mehta, 2011). In certain cases, spontaneous ADR reporting can lead to 
action being taken in the form of withdrawing the potentially unsafe medication from the market 
(Maigetter et al., 2015; Mehta, 2011)  
 
The success of any pharmacovigilance system requires a coordinated multidisciplinary team 
approach where various healthcare practitioners, including pharmacists, play a significant role 
(Jose et al., 2014). Pharmacists have a key role in the prevention of ADRs and improving the 
reporting of ADRs due to their easy access to patient medical records and their inherent 
pharmacological knowledge (Rajiah et al., 2015; Jose et al., 2014; Elkalmi et al., 2011).  
Pharmacists’ actual role in pharmacovigilance activities, their knowledge about the 
pharmacovigilance system and the factors that influence their contribution to ADR reporting may 
be different among countries (Jose et al., 2014). Suleman (2010) reported on the role of the 
pharmacist as a reporter of ADRs in the international context. Whereas pharmacists were 
traditionally associated with the dispensing of medicines and ensuring that standards are adhered 
to, this role has moved to include being a consultant on pharmacotherapy for both patients and 
other healthcare practitioners (Suleman, 2010). As pharmacists are internationally recognized as 
being the experts on medicines the question is asked what role pharmacists could or should play 
in ensuring the safe use of medicines and specifically, in the direct reporting of ADRs (Suleman, 
2010). 
 
According to Van Grootheest et al. (2004) and Zolezzi & Parsotam (2005) pharmacists should 
play a central and coordinating role in drug safety by contributing to the prevention, 
identification, documentation and reporting of ADRs. Internationally, there are various degrees 
 
 
 
 
4 
 
of reporting of ADRs by pharmacists (Suleman, 2010).  In some countries, pharmacists 
contribute substantially to ADR reporting. Examples are the United States, Canada and the 
United Kingdom, where hospital pharmacists are primarily responsible for reporting of ADRs 
(Suleman, 2010). Community pharmacists in the Netherlands, Japan and Portugal also play a 
large role in the reporting of especially ADRs related to over the counter medication (Suleman, 
2010). However, not much has been published about the reporting of ADRs by pharmacists in 
South Africa (Suleman, 2010). In the World Health Organization’s Drug Monitoring Programme 
study of 2002, South Africa ranked 29th out of a total of 39 countries in terms of pharmacists 
involvement in the reporting of ADRs (Suleman, 2010). As South Africa is lagging behind other 
upper middle-income countries concerning ADR reporting rates, the pharmacist as part of a 
multidisciplinary team could play a significant role in improving ADR reporting leading to 
increased medication safety (Aagaard et al., 2012).  
 
Antiretroviral therapy (ART) was rolled-out on a large scale in the public sector in the Western 
Cape Province in April 2004 (Venter, 2014; Mehta et al., 2008). A convergence of the 
HIV/AIDS and TB epidemics in South Africa has also been seen recently further complicating 
the management of pharmacovigilance (Mehta et al., 2008). Although developed countries have 
gained some experience with the use of ARTs, little is known about the safety of ART in 
developing countries (Ruud et al., 2010). The frequency, nature and population at risk of drug-
related harm could thus be very different compared to developed countries, where the burden of 
the two epidemics are very low (Mehta et al., 2008). Furthermore, a high number of patients on 
ART have been shown to experience at least one ADR (Tadesse et al., 2014). The management 
of ADRs in patients on ART is especially important to ensure patients’ continuation and 
motivation to stay on therapy (Ruud et al., 2012).  It is essential that a well-functioning 
pharmacovigilance system should be in place to monitor HIV/AIDS treatment programmes 
(Dheda et al, 2013).  The HIV/AIDS and TB epidemics have a major impact on the 
epidemiology of ADRs and contribute significantly to patient morbidity and hospitalization in 
South Africa (Mehta et al., 2008). Medication used in the treatment of multidrug resistant TB is 
often associated with commonly occurring ADRs that have an impact on the adherence of 
patients (Tag El Din et al, 2015).  ARV drugs and medication used to treat opportunistic 
infections commonly associated with HIV-infected individuals showed a greater tendency to 
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produce ADRs compared with drugs usually associated with producing ADRs in developed 
countries (Mehta, 2011; Ruud et al, 2010; Mehta et al., 2008). The high incidence of ADRs 
produced by medication associated with HIV/AIDS and TB epidemics coupled with the fact that 
most ADRs are preventable suggest greater involvement of pharmacists to report ADRs in South 
Africa (Mehta, 2011). Ruud et al. (2010) showed that the occurrence of ADRs and a lack of 
knowledge of patients concerning ADR information had a direct impact on treatment success and 
adherence to treatment. By promoting adherence to pharmacotherapy and improved prescribing 
and monitoring of patients’ medication, pharmacists can play a substantial role in improving 
patients’ treatment outcomes (Mehta, 2011). 
 
Resource constraints and treatment programmes focussing on HIV/AIDS, malaria and 
tuberculosis impacted on the development of pharmacovigilance systems in developing countries 
(WHO, 2011).  Most countries in the developed and developing world have spontaneous 
reporting systems in place which is cost effective and relative easier to set-up compared to other 
systems (WHO, 2011). Pharmacovigilance systems in lower income countries have however 
focussed more on medication used in public health programmes such as HIV/AIDS and malaria 
(WHO, 2011).  
 
Furthermore, due to the widespread use of herbal medicines, some African countries such as 
South Africa, Nigeria and Cameroon incorporated a focus on herbal and traditional medicines as 
part of their pharmacovigilance systems as recommended by guidelines published by the WHO 
(Kamsu-Foguem & Foguem, 2014; Shaw et al., 2012). Pharmacovigilance systems in sub-
Saharan Africa still need to see major improvement to ensure medication safety (Appiah, 2012.) 
Appiah (2012) reported on an evaluation that was done on 46 sub-Saharan countries’ readiness to 
ensure adequate medication safety. The results were not promising with most of the countries 
assessed found to have an inadequate pharmacovigilance system in place. Only four countries 
were deemed to have the ability to ensure proper pharmacovigilance safety measures (Appiah, 
2012). 
1.2. Study setting 
 
The study was conducted in the Cape Winelands District, Western Cape Province focusing on 
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the Department of Health’s clinic and hospital pharmacists. The Cape Winelands District is one 
of four rural health Districts located in the Western Cape Province. The district has a population 
of 845 237 according to the latest census (See Appendix 2, page 75). It consists of five sub 
districts namely the Breede Valley, Langeberg, Witzenberg, Drakenstein and Stellenbosch sub 
districts. The Cape Winelands District has four district hospitals, one specialized tuberculosis 
hospital, four community day centres (CDC), 45 fixed clinics, five satellite clinics and 26 mobile 
services. The Cape Winelands District employs 24 pharmacists with various degrees of 
experience, of which eight are supervisor pharmacists, supported by 54 post-basic pharmacist 
assistants. 
 
Until recently two different ADR reporting systems existed in the Western Cape Province’s 
Department of Health, one each for ART-related medication and the other for non ARV-related 
medication. (See Appendix 3, page 76 and Appendix 4, page 78). The different reporting systems 
had different reporting forms which made it more complicated to report adequately. (See 
Appendix 3, page 76 and Appendix 4, page 78). There is a new initiative in the Western Cape’s 
Department of Health to merge the two reporting systems into one system to make the reporting 
process less complicated. The current Western Cape Department of Health pharmacovigilance 
circular was issued in 2013 just after this study’s data collection was completed. (See Appendix 
5, page 86). It is envisaged that pharmacists will play a more prominent and central role in the 
proposed reporting system.   
 
1.3. Problem Statement 
 
A Spontaneous Reporting System (SRS) of ADRs forms the backbone of South Africa’s drug 
safety programme (Maigetter et al., 2015). It is well known that SRSs of ADRs are plagued by 
the phenomenon of under-reporting (Ahmad et al., 2013; WHO, 2011; Zolezzi & Parsotam, 
2005). Under- reporting delayed early detection of an ADR and led to an underestimation of the 
size of the problem in New Zealand (Zolezzi & Parsotam, 2005). Whilst in some countries 
pharmacists do report extensively (United States, Canada and United Kingdom), the reporting of 
ADRs in South Africa can be described as poor (Maigetter et al., 2015; Aagaard et al, 2012; 
Suleman, 2010). Furthermore the HIV/AIDS and TB epidemics add substantially to South 
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Africa’s burden of disease, as seen in the Eastern Cape Province, with ADRs amongst HIV–
positive patients on ART being an important cause of hospitalizations (Ruud et al., 2010). It has 
also been shown that lack of information on ADRs amongst patients has a direct impact on these 
patients’ adherence on ART, which is problematic (Ruud et al., 2010). Pharmacists in the Cape 
Winelands District could potentially play a major role in reporting ADRs, assisting other 
healthcare workers in reporting suspected ADRs and, in particular, strengthening the ART 
programme.  
Previous research conducted has highlighted several barriers that HCPs, including pharmacists, 
face that contribute to the under reporting of ADRs (Elkalmi et al., 2011; Walji et al., 2011; 
Green et al., 2001). Putting measures in place to reduce the impact of under-reporting of ADRs is 
not a straightforward process as its extent and possible local variables that impact on it are 
usually not known (Zolezzi & Parsotam, 2005). Having a better understanding of potential 
variables that could impact on under-reporting could assist healthcare managers to improve the 
pharmacovigilance system as reported conducted in a study in a New Zealand setting 10 years 
ago (Zolezzi & Parsotam, 2005).  The primary motivation for this particular study is to explore 
the perceptions and experiences of pharmacists in reporting ADRs, to gain an understanding of 
the role that pharmacists play and their knowledge of the pharmacovigilance reporting system,  
and to better  understand the barriers pharmacists might face that prevent them from participating 
in the reporting of ADRs. As it is expected that Western Cape public sector employed 
pharmacists will play a more prominent and central role in the reporting and coordinating of 
ADRs in the future, it is hoped that this study will provide recommendations to strengthen Cape 
Winelands District’s pharmacovigilance programme.   
 
 
 
 
 
 
8 
 
CHAPTER 2: LITERATURE REVIEW 
 
2.1. Introduction 
 
Previous research has reported extensively on various aspects of pharmacovigilance including 
the role various HCPs play, their knowledge and perceptions, including pharmacists, the reasons 
for under-reporting, the barriers HCPs face in practice and facilitators that could improve ADR 
reporting. These aspects vary between different settings and are influenced by a host of factors. 
This literature review focuses on factors influencing under-reporting of ADRs under three main 
themes: issues relating to the pharmacovigilance system, barriers in reporting, and facilitators to 
ADR reporting. 
 
2.2.  Issues relating to the pharmacovigilance system 
 
2.2.1. Familiarity with the ADR reporting system 
 
Whilst there are differences between countries in how their pharmacovigilance systems are 
organized and run and how they expect their HCPs to report ADRs, it is essential for HCPs to 
fully understand how a country’s pharmacovigilance functions for them to report ADRs 
adequately (Van Grootheest et al, 2004). It has been found that when HCPs do not know that 
such a system exists and how the reporting system is organized, it has a detrimental effect on the 
number of ADRs that will be reported (John et al., 2012; Fadare et al, 2001; Palaian et al., 2011). 
Elkalmi et al. (2011) found that most respondents in their study were not aware of a 
pharmacovigilance system and showed a lack of awareness of the previously issued reporting 
guidelines (Elkalmi et al, 2001). HCPs need to be familiar with certain aspects of the 
pharmacovigilance system such as the ADR reporting form in order to report successfully 
(Elkalmi et al, 2011). They also found that most participants were not aware of ADR reporting 
forms while some had come across them by chance. This lack of knowledge and familiarity of 
how the reporting process worked had a detrimental impact on reporting (Elkalmi et al., 2011).  
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2.2.2. Gaps in the ADR reporting system 
 
Gaps in the pharmacovigilance reporting system could include the unavailability of or no access 
to reporting forms, a lack of an address where to send the ADR reports and a lack of guidelines 
to ensure that continuous awareness is maintained (Elkalmi et al, 2011). Elkalmi et al. (2011) 
mentioned a lack of address to send the reports to and unavailability of the reporting forms as 
gaps in the reporting system in Malaysia. In resource-poor settings such as in Africa, where 
telecommunication infrastructure is often found wanting, a lack of resources might result in 
completed forms not reaching the central reporting centre and feedback might not reach the 
reporters (Sevene et al, 2008). Oreagba (2010) reported that 88% of pharmacist respondents in a 
study done in Nigeria claimed that they did not have access to ADR reporting forms and 
highlighted this as an important factor why they did not report. 
 
2.2.3. Complexity of the ADR reporting system 
 
Where healthcare workers, including pharmacists, perceive the reporting process or the reporting 
form as too complicated, results have shown that this negatively affects their willingness to 
report ADRs (Elkalmi et al., 2011; Ruud et al., 2010). A complex form may be perceived by 
pharmacists as requiring more time to complete, in an already challenging workplace 
environment where time is limited (Walji et al., 2011).  Even if the reporting form is 
straightforward to complete, the reporting route might be perceived as being complicated by 
HCPs (Elkalmi et al., 2011).  
 
2.2.4. Attitudes and behaviors towards ADR reporting  
 
An international journal review found that under-reporting of ADRs is strongly associated with 
specific attitudes of HCPs to ADRs and the reporting system (Lopez-Gonzalez et al., 2009). For 
pharmacists to report ADRs on a continuous basis, it is essential that they view the reporting of 
ADRs as part of the pharmaceutical care provided by them. (Walji et al., 2011). Elkalmi’s et al. 
(2011) study in Malaysia highlighted the fact that a pharmacist’s perception of his or her 
professional role played the greatest part in determining whether ADRs for natural health 
products would be reported or not. Where pharmacists exhibited a broader view of their 
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professional role and responsibility, it was found that they were more likely to report ADRs and 
less likely to be influenced by workplace challenges that prevented others from reporting (Walji 
et al., 2011). Elkalmi et al. (2011) reported that most pharmacists saw the reporting of ADRs as 
part of their pharmaceutical care role and acknowledged the importance of ADR reporting.  
 
Summers et al. (2013) reported on an interactive workshop on pharmacovigilance at the SAAHIP 
2013 National Conference which allowed participants to decide for themselves whether 
pharmacovigilance is a vital tool for the pharmacist or a wasted effort (Summers et al, 2013). 
The survey found that few of the participants practise pharmacovigilance actively, despite the 
fact that the great majority (n = 90) rated pharmacovigilance as either important (39%) or very 
important (58%) in their everyday work (Summers et al, 2013). 
 
Even though pharmacists agreed that it was part of their professional responsibility to report 
ADRs and acknowledged the importance of ADR reporting, reporting was found to have been an 
uncommon occurrence in their careers. (Suyagh et al., 2015; Jose et al., 2014; Elkalmi et al., 
2011; Walji et al., 2011; Green et al., 2001) 
 
Pharmacists acknowledge that the responsibility for reporting ADRs is shared with other 
healthcare providers such as doctors and nurses (Walji et al., 2011).  This overlapping 
responsibility leads many pharmacists to refer a potential ADR to another healthcare provider or 
co-operate with them rather than reporting it themselves (Walji et al., 2011).  On the other hand, 
an early study indicated that some pharmacists do not report ADRs because they assume another 
HCP will report the suspected ADR (Green et al., 2001). This could also have been due to some 
pharmacists feeling apprehensive about sending in ‘inappropriate’ reports (Green et al., 2001). 
Passing the responsibility to others might lead to a loss of follow-up on the ADR (Walji et al., 
2011).  Where pharmacists took a more involved role in reporting ADRs they were less likely to 
pass on the responsibility of reporting ADRs to other healthcare workers. (Walji et al., 2011).  
Although pharmacists might acknowledge the importance of reporting of ADRs, they do not 
necessarily regard it as a major priority compared to other more pressing matters such as stock 
control, paperwork, and human resource management matters (Walji et al., 2011). 
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Walji et al. (2011) reported on pharmacist interventions when confronted by patients reporting an 
NHP-related ADR. Pharmacists either recommended that patients discontinue using the 
suspected product, or advised the use of another product to lessen the effects of the reaction or 
replacing the product with a different one (Walji et al., 2011).  Although pharmacists were 
concerned about the safety of the presenting patients, they nevertheless failed to see the 
importance of reporting the ADR to make a contribution to the safety of other patients (Walji et 
al., 2011). 
  
2.3. Barriers to reporting ADRs 
 
Several barriers have been identified which hinder pharmacists from reporting ADRs. These 
include a lack of knowledge and skills, a heavy workload or time constraints and a lack of 
feedback. Elkalmi et al. (2011) reported that previous studies identified a number of barriers that 
prevent pharmacists from reporting ADRs, including the unavailability of the reporting form, 
pharmacists not knowing what to report on, fear of legal liability, lack of time, pharmacists being 
unsure about the cause of the ADR and ADRs being too well known or simplistic to report on. 
2.3.1. Heavy workload and time constraints 
 
A heavy workload and time pressures continually came up as a major barrier to reporting across 
various categories of healthcare providers in different countries (Walji et al., 2011). Respondents 
previously reported that they just did not have the time to report ADRs (Green et al, 2001). In a 
resource-constrained environment where pharmacies are under-staffed, other matters seem to 
have a higher priority, as reported earlier (Walji et al., 2011). In South Africa, work and time 
constraints as experienced by healthcare workers have been reported as a serious limiting factor 
in reporting ADRs (Suleman, 2010). This can be attributed to working in stress full 
environments, and managing increasing patient numbers and dealing with staff shortages. (Ruud 
et al., 2010). Elkalmi et al. (2011) reported that some pharmacists perceive medical officers as 
being very busy which impacts on the working relationship between the medical officers and 
pharmacists as medical officers might not respond to pharmacists’ queries. Most pharmacists 
complained of a heavy workload and the reporting of ADRs was seen as just additional 
paperwork added to the busy schedule of healthcare workers (Ruud et al., 2010). 
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2.3.2. Lack of knowledge and skills 
 
A lack of clinical knowledge and a lack of understanding of what should be reported were found 
to have a major impact on ADR reporting amongst healthcare workers (Suleman, 2010; Green et 
al, 2001). Oreagba et al. (2010) reported that pharmacovigilance knowledge amongst community 
pharmacists in Nigeria was poor which partially explained the poor reporting of ADRs. Where  
knowledge is lacking, HCPs could fail to identify an ADR in the first place (Ruud et al., 2010). 
A lack of knowledge could be attributed to previous healthcare policy priorities (Ruud et al., 
2010). With the roll-out of the ART programme in the Eastern Cape, initial emphasis was placed 
on more to the delivery of ARV’s without the necessary focus on pharmacovigilance practices 
(Ruud et al., 2010). Ruud et al. (2010) reported on nurses who generally prescribed pain 
medication for the relief of pain without considering that it could be as a result of an ADR (Ruud 
et al., 2010 ). A lack of knowledge could also lead to a lack of confidence to refer and report 
ADRs (Ruud et al., 2010). Ruud et al. (2010) found that although patients’ ADRs might have 
been identified, patients were referred for treatment purposes only, without formally reporting 
the ADR for pharmacovigilance purposes (Ruud et al., 2010).  
 
Pharmacists did not always understand clearly what should be reported (Zolezzi & Parsotam, 
2005; Green et al., 2001). In South Africa, most HCPs, including pharmacists, have indicated 
that they had a lack of understanding of what should be reported and that they lacked the 
knowledge and skills to identify ADRs (Suleman, 2010). Where ADRs are considered to be well-
known and of little importance clinically, the chances that they will be reported could be reduced 
(Elkalmi et al, 2011).  HCPs tended to be more likely to report an ADR if it is serious or rare 
(Walji et al., 2011). Furthermore, although a suspected ADR might be classified as serious or 
rare, this does not necessarily mean that it will be reported due to pharmacists wanting to be sure 
that the causality can be traced back to the drug in question ( Walji et al., 2011). Green et al. 
(2001) reported that a higher proportion of pharmacists compared to hospital doctors report 
serious reactions and a lower proportion of reports  involved reactions attributed to newly 
marketed drugs ( Green et al, 2001).  
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Pharmacists were found to  want to be sure about what could have potentially caused the 
suspected ADR before they reported the reaction to prevent them from looking  incompetent  
(Green et al, 2001). Elkalmi et al. (2011) reported that most pharmacists only reported if they 
were sure about the cause of the ADR. A lack of knowledge of the legal liabilities concerning 
ADR reporting could also have a negative impact on reporting (Ahmad et al., 2013; Zolezzi & 
Parsotam, 2005). Where pharmacists were unsure of any potential comebacks when they 
reported ADRs, they might have been reluctant to report ADRs in the first place (Zolezzi & 
Parsotam, 2005). This can be overcome by establishing a reporting culture where HCPs feel 
confident to report ADRs without facing any penalties (Ashcroft, 2006).  
2.3.3 Lack of feedback 
 
An important barrier routinely mentioned in previous research is the lack of feedback provided to 
HCPs of ADRs (Ruud et al, 2010; Zolezzi & Parsotam, 2005; Green et al, 2001). No or minimal 
feedback to reporters, including confirmation of reports received, discourages the continuous 
reporting of ADRs (Elkalmi et al., 2011; Ruud et al., 2010; Suleman, 2010; Olsson et al., 2010).  
Individual feedback should be provided to pharmacists who submitted reports. General feedback 
in the form of guidelines based on trends were recommended as part of a pharmacovigilance plan 
(Elkalmi et al., 2011). Poor communication and feedback were found in a survey conducted at a 
national pharmacovigilance stakeholders workshop held in South Africa in 2012, to be one of the 
major weaknesses in current pharmacovigilance systems (Mehta et al, 2013).  
 
2.4. Facilitators to reporting ADRs 
 
Various facilitators or enablers have been reported to help improve the reporting of ADRs. These 
can be classified as ways that aim to strengthen the reporting system, educational interventions 
and incentives to improve reporting. 
2.4.1 Strengthening and facilitating the reporting system 
 
Continuous awareness campaigns were needed to be implemented to raise the importance of 
ADR reporting amongst HCPs (Fadare et al., 2011). Healthcare workers should also have an 
adequate understanding of the reporting process and how it is organized (Elkalmi et al., 2011). It 
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was recommended that the reporting form should be as simple as possible to enable a more 
convenient reporting process (Elkalmi et al., 2011). It has been recommended that ADR 
reporting forms should be available and always accessible and that there should be no doubt as to 
where the reporting form needs to be sent (Elkalmi et al., 2011). One way of improving the 
accessibility of the reporting form was to provide reporters with the option of web-based 
reporting (Molokhia, 2009). 
 
A focal person being tasked to facilitate and strengthen the reporting process should be 
especially considered in resource-constrained environments (Sevene et al, 2008). The pharmacist 
can play such  a key role in various settings and help coordinate the reporting process and 
compensate for any inherent flaws and challenges in the system ( Sevene et al, 2008). The 
presence of clinical pharmacists in the wards and their constant encouragement might help 
improve the rate of reporting amongst other HCPs while at the same time lead to a decrease in 
the avoidable Adverse Drug Events including ADRs. (Arulmani et al., 2008; Green et al., 2001).  
2.4.2 Educational interventions 
 
It has been shown that educational interventions considerably improve rates of reporting 
although this benefit decreases with time (Kabanywanyi et al., 2010; Molokhia, 2009). 
Continuous education is needed to increase the clinical knowledge of healthcare workers to 
enable them to identify ADRs and have the confidence to report them (Oreagba et al., 2010; 
Molokhia, 2009; Green et al, 2001). Training was in the form of regular workshops and seminars 
aimed at improving the pharmacist’s detection skills and updates related to the ADR reporting 
process were disseminated (Elkalmi et al, 2011). Sevene (2008) reported that an improvement 
was seen in the rate of reporting after a pharmacovigilance training session was conducted 
(Sevene et al., 2008). ADR reporting guidelines in the form of booklets and posters were 
recommended to be readily available and placed in easy to find locations in healthcare facilities 
(Fadare et al., 2011).  
2.4.3 Providing incentives to report 
 
Elkalmi et al. (2011) reported that the majority of the pharmacists interviewed did not prefer 
monetary incentives but rather expressed a need for incentives in the form of awards and journal 
subscriptions (Elkalmi et al., 2011). However, community pharmacists in a Nigerian study 
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believed that remuneration might well lead to an increase in the number of reports (Oreagba et 
al., 2010). Green et al. (2001) recommended that health care practitioners, including pharmacists, 
should be continuously motivated by management to report ADRs. In South Africa, it has been 
reported that HCPs are poorly motivated to produce quality data because most data collected are 
irrelevant to their own information needs (Suleman, 2010). 
 
2.5. New initiatives and recent developments 
 
Several recent innovations and developments have been reported on that have relevance for 
South Africa.  These include the Kenyan electronic reporting system, recommendations for a 
new South African National Pharmacovigilance Plan and a decentralized pharmacovigilance 
reporting system piloted in Mpumalanga province, South Africa. 
2.5.1 The Kenyan Electronic reporting system 
 
The Kenyan Pharmacy and Poisons Board (PPB) began establishing a process of monitoring and 
reporting ADRs in 2004, and the Kenyan National Pharmacovigilance System was officially 
launched on June 9, 2009 (Otieno, 2013). Kenya became the first country in Africa, and in the 
world, to use a digital reporting tool for pharmacovigilance based on mobile technology (Otieno, 
2013). 
 
Like other countries, Kenya relied on manual reporting using printed forms in the past (Otieno, 
2013). Two forms were historically used, a yellow form for reporting suspected ADRs and a 
pink form for reporting suspected poor-quality medicines (Otieno, 2013). 
Managing a manual system is a cumbersome and tedious process compared to an electronic 
system, due to the fact that the authorities had to make sure that the forms were printed and 
transported to various health care facilities throughout the country. Furthermore, reports 
submitted to the National Pharmacovigilance Centre had to be entered manually into the WHO 
recommended database, which all added to costs and loss of time (Otieno, 2013) The new digital 
system, which was launched on April 23, 2013, is a paperless system and can be downloaded 
either on a computer or a smart phone, or the report can be made directly to the PPB on their 
website. 
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Significant improvements were immediately seen after the implementation of the electronic 
system such as an increase in the number of ADR and poor product quality reports submitted 
which resulted in the PPB quarantining, recalling, or withdrawing some medicines (Otieno, 
2013). One specific action taken because of reports submitted via the new electronic system 
resulted in the closure of a pharmaceutical company that was not meeting legislative 
requirements. 
2.5.2 Recommendations for a South African National Pharmacovigilance 
Plan 
 
Mehta (2013) reported on the findings and recommendations of a South African national 
pharmacovigilance workshop that was held in 2012. The aim of the workshop was to obtain an 
overview of non-regulatory pharmacovigilance activities being conducted in the public sector in 
support of a national pharmacovigilance plan (Mehta et al., 2013). The workshop identified key 
strengths, challenges, and opportunities in improving the coordination of pharmacovigilance 
activities and operations (Mehta et al, 2013).   
 
The workshop had the opinion that the national pharmacovigilance plan must encompass five 
key principles (Mehta et al, 2013). Firstly, all pharmacovigilance systems should be incorporated 
into a unified national system (Mehta et al., 2013).  Furthermore, the data generated from the 
national pharmacovigilance system should contribute to treatment, policy decision-making and 
improved patient care especially at primary healthcare level (Mehta et al., 2013). The national 
pharmacovigilance system should incorporate both passive and active surveillance methods and 
should continue with systems that already exist and have shown success (Mehta et al., 2013). 
What is also needed is investment in capacity building and training in pharmacovigilance and 
pharmaco-epidemiology which will contribute to the success of the system (Mehta et al., 2013). 
Lastly, feedback and communication to all stakeholders and role-players must be prioritized to 
ensure the success of the new pharmacovigilance programme (Mehta et al., 2013).   
 
One of the recommendations of the workshop was the creation of a national pharmacovigilance 
website that can enable the sharing of information sharing between role-players and stakeholders 
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(Mehta et al., 2013). This electronic data management system should be developed by the 
Department of Health and make provision for routine analysis, reporting of data and feedback to 
reporters and other relevant stakeholders (Mehta et al., 2013).   
 
The National Department of Health has already started implementing some of the workshop’s 
recommendations (Mehta et al., 2013). This included the appointment of a co-coordinator to 
facilitate implementation and the creation of a national decentralized Targeted Spontaneous 
Reporting system for HIV and TB in six provinces (Mehta et al., 2013). Spontaneous reports 
generated by this decentralized reporting system are reviewed by a sub-district multidisciplinary 
health team to identify trends, preventable factors and system errors (Mehta et al., 2013).   In 
addition to the above, the National Department of Health is also implementing a national 
pregnancy exposure registry and birth defect surveillance programme at certain specified sites to 
assess the safety of medicines used in pregnancy (Mehta et al., 2013).   
 
2.5.3 Decentralized pharmacovigilance pilot programme in Mpumalanga province 
 
Dheda (2013) reported on a pilot-project, which involved setting up a decentralized 
pharmacovigilance reporting programme focusing on ART in Mpumalanga province in South 
Africa. As part of the programme intervention, HCPs, which included pharmacists, were first 
trained in pharmacovigilance aspects through training workshops (Dheda, 2013). During the 
training workshops, HCPs were asked whether they had encountered any ADRs in practice 
(Dheda, 2013). The HCPs reported that all of them encountered an ADR in practice but that the 
chances of them actually reporting it were less than 50% (Dheda, 2013). Dheda (2013) reported 
that the spontaneous reporting system showed serious limitations, struggled with under-reporting 
and provided poor pharmacovigilance outcomes in South Africa. The poor performance of the 
spontaneous reporting system was evident based on the low number of reports received by the 
NPC which does not have the capacity to give guidance on all reports received (Dheda, 2013). 
Furthermore, the current spontaneous reporting system was never designed to assist in the 
management of patients at local clinical settings (Dheda, 2013). What is needed is a more robust 
system that can accommodate a rapidly expanding ART programme and integrate 
pharmacovigilance activities into the daily clinical operations at primary health care level 
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(Dheda, 2013).   
 
The decentralized system consisted of multidisciplinary teams established at selected clusters 
(Dheda, 2013). These multidisciplinary team clusters were trained to discuss individual cases and 
provide treatment options (Dheda, 2013). It was found that this approach increased the number 
of reports seen at primary health care level (Dheda, 2013). These clusters would still be 
supported by the NPC through follow-up communications including phone calls, faxes or emails 
(Dheda, 2013).  The NPC would however be required to analyze reports received by the different 
clusters and provide appropriate feedback on emerging trends (Dheda, 2013).  
 
The successful implementation of the decentralized pharmacovigilance pilot programme in 
Mpumalanga Province was followed by a roll-out to the North West Province 
(Siapsprogram.org, 2016). The rollout of the decentralized programme in the North West 
Province resulted in positive outcomes which include the training of 118 HCPs, the 
establishment of 20 clusters in 256 health facilities, the use of new, revised ADR forms and the 
creation of a NPC information bulletin for the North West Province (Siapsprogram.org, 2016). 
 
2.6. Conclusion 
 
Although previous researchers have reported extensively on the phenomenon of under- reporting 
of ADRs by various HCPs including pharmacists, minimal research was conducted using 
qualitative methodology, to explore the situation especially in the South African context.  It is 
hoped that this qualitative study will provide an improved understanding of the perceptions and 
experiences of public sector pharmacists in the South Africa, with the aim of improving the 
pharmacovigilance system. 
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CHAPTER 3: METHODOLOGY 
 
3.1. Aim 
To investigate the perceptions and experiences of reporting of adverse drug reactions by public 
sector pharmacists employed in the Cape Winelands District.  
 
3.2. Objectives 
1. To explore pharmacists’ perception of their role in reporting ADRs.  
2. To describe the knowledge and understanding of pharmacists on the ADR reporting 
system in Cape Winelands District of the Western Cape Province. 
3. To explore the barriers that prevent pharmacists from reporting ADRs. 
3.3. Study Design 
 
A qualitative study design was previously used to explore the perceptions and experiences of 
pharmacists reporting ADRs (Smith, 1998). Since such methods can be effectively used to 
explore complex practice-orientated phenomena, such as issues related to roles and 
responsibilities, this approach was followed.   
 
3.4. Sample population, size and procedures 
 
The primary study population consisted of 24 public sector pharmacists in the Cape Winelands 
District. A purposive sampling methodology was utilized. This method involved the deliberate 
identification and selection of particular individuals with certain characteristics and experiences 
and has been described by Smith (1998). In this study 16 pharmacists ranging in gender, age, 
experience and rank were selected.  It was envisaged that they would provide a broad range of 
perspectives and be the most informative in achieving the objective of the study. Eight 
pharmacists were supervisor pharmacists while the rest were production pharmacists, including a 
community service pharmacist and an intern pharmacist. Supervisor pharmacists are more 
involved with managerial tasks and the attendance of meetings compared to production 
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pharmacists who focus on patient care and dispensing of medication. Two key stakeholders 
involved in the Western Cape Pharmacovigilance System were also included in the study.  
 
One of them was a policy specialist pharmacist working at Directorate: Pharmacy Services and 
primarily involved with the Provincial Pharmacy and Therapeutics Committee. The other, at the 
time of the study, was the manager of the Medicines Information Centre which forms part of the 
University of Cape Town’s (UCT) Pharmacology Division. Both were highly experienced 
pharmacists familiar with the pharmacovigilance system. 
 
It was anticipated that the primary sample size for this study would be between 10 and 16 
participants due to the relatively narrow focus of the study. Similar qualitative studies conducted 
by Elkalmi (2011) and Walji (2011), investigating the under –reporting of ADRs among 
community service pharmacists, reported a sample size of between 10 and 16 participants 
(Elkalmi et al, 2011; Walji et al., 2011). Elkalmi et al. (2011) conducted a qualitative study 
exploring barriers and facilitators amongst community pharmacists reporting ADRs in Malaysia. 
Walji (2011) conducted a qualitative study amongst community service pharmacists in Canada 
investigating the pharmacist’s responsibility in reporting natural health product related ADRs. 
 
3.5. Data Collection 
 
Data were collected between August and October 2013 through in-depth interviews using a 
semi-structured interview guide consisting of open-ended questions (See Appendix 6, page 95). 
Questions used in the interview guide were initially based on findings in the literature review 
(Smith, 1998). Open-ended questions encouraged respondents to freely express their views. It 
was anticipated that initial emerging themes would include workplace barriers to ADR reporting, 
perceptions of roles and responsibilities towards ADR reporting and awareness of the 
spontaneous reporting system procedures. Probing questions were used where the interviewers 
felt that a need existed to clarify some of the participants’ responses. Care was however taken 
not to ask leading questions by briefing the interviewers beforehand on the dangers of this 
practice. 
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The semi-structured interview guide was pre-piloted with one pharmacist who did not form part 
of the primary study population to identify any potential problems. Although the primary 
interview guide was not amended, as the interviews were conducted with the participants, the 
interviewers became more aware of certain recurring themes that made them more sensitive in 
probing certain responses of participants. The same interview guide was used to interview the 
key stakeholders, although the probing questions differed with this category of respondents 
compared with the primary study population. 
 
The assistance of researchers (data collectors) of a local NGO partner, ANOVA, was sourced to 
conduct the data collection. They were experienced in qualitative research methods. A meeting 
was conducted beforehand with the two data collectors to brief them on the purpose of the study 
and to explain the semi-structured interview guide. As the researchers were not pharmacists, time 
was spent in explaining some pharmacy concepts to them such as patient counselling, the study 
setting, operational matters and briefing them in the different roles pharmacy personnel play. It 
was anticipated that the interviews would be conducted in English, as all pharmacists in the study 
have a good level of English. The data collectors found however that some pharmacists 
conversed more comfortably in Afrikaans. The data collectors were made aware of this. In 
practice eight interviews were conducted in English and eight in Afrikaans.  
 
All interviews were tape-recorded by the two independent data collectors using a digital 
recorder. The data collectors were asked to make field notes recording the additional contextual 
information such as tone of voice and non-verbal clues. Venues to conduct the interviews were 
arranged and negotiated with the Department of Health, as it was deemed to be the most 
convenient for the pharmacists to be interviewed at their place of work. Duration of interviews 
ranged between 20 minutes and 30 minutes.  
 
3.6. Data Analysis 
 
All interviews were transcribed verbatim by the investigator. Data analysis involved categorizing 
the data into themes using a coding process. Topics from the semi-structured interview guide 
were initially used as categories for the coding process. The coding framework was organized as 
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a simplistic, structured Excel spreadsheet. Initial themes used were revised as new topics 
emerged during the analysis.  
 
3.7. Validity 
 
The validity of the data refers to the extent to which it is an accurate reflection of the phenomena 
being investigated (Smith, 1998). The topic was explored as far as possible through the use of 
open-ended questions allowing the direction and the content of the interview to be guided by the 
interviewer. Here the data could be seen as possessing an ‘inherent’ content validity (Smith, 
1998). Respondent validation or “member checking” was conducted during individual interviews 
to clarify certain points. Here, a respondent’s answers to questions were, in some cases, repeated 
to encourage clarification by the respondent. Validity was further ensured through the interview 
of key informants familiar with the reporting process. A clear account of the data collection, 
analysis and detailed descriptions of parameters has been presented in this research report. This 
allows readers to judge whether the interpretation of the findings are in line with the data 
collected and analyzed. In addition, the researcher continuously reflected on the data during the 
analysis and presentation of the results of the study. 
 
3.8. Limitations 
 
Only 16 pharmacists were interviewed in this study which could be seen as one of its limitations. 
Whilst this number was in line with participants selected for other qualitative investigations 
focusing on under-reporting of ADRs by pharmacists, in qualitative research the topic of interest 
is usually explored until saturation of the data is reached, meaning no new information is 
forthcoming from the study participants (Elkalmi et al., 2011; Walji et al., 2011). However, in 
view of the limited scope of the mini-thesis and the narrow focus of the research, this number 
was determined acceptable.  
 
The investigator is the pharmacy manager of the Cape Winelands District and thus familiar with 
the study participants. This could be viewed as a potential source of bias that could influence the 
results obtained. This was overcome by the investigator enlisting the assistance of two data 
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collectors who had previous qualitative research experience and a basic understanding of the 
study context. The investigator conducted the interviews with the two key stakeholders. 
informants. All interviews were tape recorded. The recordings revealed discussions with 
pharmacists were without fear and restrictions. It appeared that the investigator’s working 
relationship with the pharmacists, as their district pharmacist, did not negatively influence 
information shared by the pharmacists interviewed in the study. 
 
The fact that only rural pharmacists were interviewed has an impact on the generalizability of the 
findings as other HCPs, pharmacist’s assistants, pharmacists and other cadres in the metro 
districts were not interviewed. Consequently, the findings of this study have relevance to rural 
pharmacists in this setting but could be applicable to pharmacists in similar rural districts in 
South Africa. 
  
3.9. Ethics 
 
Ethical approval of the study was received from the University of the Western Cape Senate 
Research Committee (Registration No: 12/10/31) and permission to conduct it from the Western 
Cape Department of Health Research Committee (Appendix 7, page 99). Before participating, all 
respondents were supplied with an information sheet giving detailed information about the study 
(See Appendix 8, page 100). Thereafter written informed consent was obtained from each 
respondent participating in the research study (See Appendix 1, page 73). Participants were 
informed that they could withdraw from the study any time if they felt the need to do so. They 
were informed that they would not be adversely affected in any way. Information gained in the 
research study would not be used against them in any way. Confidentiality was maintained at all 
times and transcripts were stored securely with only the interviewer and primary researcher 
having access to the transcripts. The findings of the study will be made available to all 
participants. Information gained from this study will also be made available to the district 
management of Cape Winelands District, the Western Cape Provincial Pharmacy and 
Therapeutics Committee and Provincial Pharmacy Services sub-directorate. 
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CHAPTER 4: RESULTS 
 
4.1. Introduction 
 
The interview respondents consisted eight supervisor pharmacists and eight production 
pharmacists. One intern pharmacist and one community service pharmacist were included under 
the category of production pharmacists. Two key stakeholders who had extensive experience of 
the pharmacovigilance system in the Western Cape Province were interviewed. Please see Table 
1 for additional information including gender, years of service and the institution type where the 
pharmacists were employed. 
Table 1: Demographics of the respondents 
Pharmacist Type of Pharmacist Gender Years of 
service 
Institution Type 
SP1 Supervisor Female 10 years District Hospital 
SP2 Supervisor  Male 7 years CDC 
SP3 Supervisor Male 36 years CDC 
SP4 Supervisor Male 21 years CDC 
SP5 Supervisor Male 7 years TB Hospital 
SP6 Supervisor Female 13years CDC 
SP7 Supervisor Female 10 years District Hospital/CDC 
SP8 Supervisor Male 8 years District Hospital/CDC 
PP1 Production Male 5 years CDC 
PP2 Production Male 29 years CDC 
PP3 Production Female 5 years CDC 
PP4 Production Female 10 years CDC 
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PP5 Production Female 15 years CDC 
PP6 Production (CSP) Male 2 years CDC 
PP7 Production Male 22 years TB Hospital/ CDC 
PP8 Production (Intern) Male 10 months District Hospital 
K1 Policy Specialist Female 25 years Head Office 
K2 Manager  Female 21 years Medicine Information Centre 
 
One of the objectives of the study was to explore pharmacists’ perceptions of their role in the 
reporting of ADRs. The selection of the supervisor pharmacist category aided the investigation 
of this objective. One of the themes that surfaced during the exploration of this objective is the 
pharmacist’s role as gatekeeper and driver of the reporting process. Another theme that emerged 
was the perception of the importance of ADR reporting. 
Another objective was to describe the knowledge and understanding pharmacists have of the 
reporting process. Two themes that emerged here were the variance in knowledge of the 
reporting system between supervisor pharmacists and production pharmacists and the under-
reporting observed in the system.  
As barriers were well described in previous literature, a main objective was to explore the 
barriers that pharmacists experienced in this specific study setting. A lack of feedback was one of 
the main barriers associated with this objective. 
4.2. The role of the pharmacist in ADR reporting 
 
4.2.1. Pharmacists as the gatekeepers and drivers of the reporting process 
 
Pharmacists identified strongly with being the gatekeepers and the drivers of the reporting 
process.  They associated their gate keeping role with being the custodians of medicine and 
ensuring patient safety with respect to medicines. Their gate-keeping duties included assisting 
other healthcare workers in the reporting process, such as giving telephonic advice, answering 
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ADR reporting queries, helping to identify ADRs, ensuring the availability of reporting forms, 
the collation of forms, making sure the forms were submitted and conducting surveillance on 
new generic brands.  Some pharmacists indicated that the position of the pharmacist in the 
healthcare delivery chain facilitated their gate keeping duties, particularly the collation and 
submission of forms. Patients are often seen first by other healthcare professionals before they 
access their medication at the pharmacy. As the pharmacist is usually the healthcare professional 
that sees the patient last, the pharmacist has a governance role to reduce possible under-reporting 
by other healthcare workers. 
“So the pharmacist would play a key role, most of the reports that you would get from a patient 
that experienced an ADR, they would probably come back to the pharmacist because he is the 
end point, he was the last person to give the medication to the patient, so the pharmacist is key.” 
-PP6 
 Most pharmacists indicated that they felt they should be the drivers of the reporting process.  
“Most definitely I think we as pharmacists should take the lead in it… But we should really be 
the drivers and the force behind it.” – SP2 
Creating awareness through regular meeting structures such as the local PTC, clinical M&M 
meetings and other meetings with the doctors was one way pharmacists proposed that they could 
drive the reporting process. Pharmacists also mentioned workshops as a means to create 
awareness. One pharmacist indicated that creating awareness is an on-going process. Another 
indicated that ADR reporting increases after an awareness event but that it decreases after two 
months. 
“So I think it is important what you say that it is something that is continuous, it is something 
that flows, if you don’t get the message out…You have to keep momentum...”- SP6 
The key stakeholders confirmed that pharmacists have an important role to play. They indicated 
that pharmacists are the custodians of medicine and should put systems in place to ensure that 
reporting occurs, motivate other healthcare workers to report suspected ADRs and make sure that 
healthcare workers have access to the forms.  
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 “I think the role of the pharmacist is to encourage other people to report, to create awareness of 
the actual harms that medicines can cause.”- K2  
 
4.2.2. The responsibility of the pharmacist in reporting ADRs 
 
Pharmacists indicated that they are responsible for the reporting of ADRs because they are the 
custodians of medicines. They believed that they are responsible for promoting and encouraging 
ADR reporting because better reporting would improve the safety of medication. Some 
pharmacists indicated that they should conduct surveillance on new generic brands of medication 
to ensure the patients’ safety. They mentioned that new generic brands of medication could have 
quality issues that should be detected by pharmacists.  
“…but some people experience more adverse effects with especially if you changed the 
brand...”- SP2 
Pharmacists spoke of their pharmaceutical care role and their capability in reporting ADRs. One 
pharmacist indicated that counselling of patients about their medication needs is part of the 
pharmacist’s pharmaceutical care role. 
“…depending on the severity of it, we would counsel the patient and tell him next time he sees 
the doctor he needs to report the ADR, so that the doctor is aware of it. If it is so severe that he is 
not going to take his medication then obviously you have to step in straight away.”- PP5 
 Through counselling sessions, the patient has an opportunity to disclose to the pharmacist about 
a potential ADR that the patient may be experiencing. However, in practice, pharmacists would 
rarely report an ADR from evidence obtained in a counselling session but would usually refer the 
patient to the medical officer.  
 Two pharmacists remarked that in the past, patients were not sensitised to possible side-effects 
and ADRs that they might experience, for fear that that they might over-report the reactions.   
“…but we don’t talk to patients a lot about side-effects, because we are afraid that they would 
think that they do have side-effects…”- SP6 
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Some pharmacists indicated that they are aware that when the branding of a medicine changes, 
this may have a psychological effect on the patient who may then report that the medication has 
a different effect than before.   
“Sometimes a patient might look at a pill that is yellow, and it used to be green and now it 
suddenly does not work, then I would be unsure about it, is it in his head or is it really the case. 
It can be that it might not work, so you have to keep your eye on it.”- SP3 
Pharmacists had varied opinions about whether they felt capable to report and identify ADRs.  
“...yes. I feel capable.” – SP4 
“…No I don’t feel ... I think the problem might be the working conditions under which people are 
operating nowadays.” – SP8 
From what pharmacists reported, it seems that most potential ADRs are identified by pharmacy 
staff reading patient folders.  Doctors’ notes in the folders often provide clues about whether a 
patient experienced an ADR or when a patient’s medication was changed.  Pharmacists would 
then report an ADR directly from the doctor’s notes. 
 “... I filled in the form according to his notes...”- PP8 
 The key stakeholders reported that pharmacists should play the gatekeeper role and enable other 
healthcare workers to report ADRs and not report themselves. One key stakeholder respondent 
left the door open for pharmacists to report only from the doctor’s notes. The other key 
stakeholder had the opinion that pharmacists should only perform the gate-keeping duty as they 
do not have the capacity or the clinical knowledge and should therefore not conduct direct 
reporting of ADRs. 
“The pharmacist should maybe be the one that keep the forms and make sure that people fills 
them in and sends them on but I do not think they should actually be filling in the form, I think 
the nurse or the doctor who has the patient in front of them should possible be filling in the 
form.” – K2 
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“I know it is supposed to be the pharmacist’s role to report and to fill in the forms, but actually 
they do not actually see the patient and the form requires you to actually have some clinical 
knowledge of the patient.”-K2 
“… then they can investigate further but in this point in time they do not have the capacity, or the 
ability or the situation to do that kind of work, so maybe just as a gatekeeper.”- K1  
“… but I don’t think they will pick it up with a patient, because they don’t talk to a patient, but 
they can pick it up in folder.”- K1 
Interestingly, the intern pharmacist remarked that the responsibility to report ADRs might stem 
from the fact that pharmacists studied pharmacovigilance as part of their curriculum.  The intern 
pharmacist questioned whether pharmacovigilance was part of the doctors training curriculum. 
“Yes, especially the pharmacovigilance aspect, because that is something that you study at 
university. I am not sure if the doctors have pharmacovigilance as a topic, do they cover it, and I 
know I covered it so that is why I feel I have got a responsibility,…”- PP8 
Some pharmacists indicated that a pharmacist can’t really report an ADR because only the 
medical officer has the authority to change a patient’s prescription. One pharmacist reported that 
ADRs cannot be identified merely through observations and patient counselling. Only through 
clinical tests and thorough examination of the patient can one identify an ADR and this does not 
form part of the scope of practice of a pharmacist. 
“Sometimes you would see a reaction but then you would send the patient back, because you 
can’t just speculate, you can’t pin point something if you have not done a blood test or 
something. So in most cases you would refer the patient back to the doctor.” - PP7 
According to some pharmacists, patients should only report ADRs to the medical officers. This 
belief may explain why patients are referred back to the medical officer if they expressed a 
problem at the pharmacy.  Some pharmacists indicated that when patients report ADRs to the 
pharmacists they are asked why they did not report it to the medical officers in the first place. 
One pharmacist indicated that even if they do report an ADR, they must still send the patient 
back to the medical officer to change the prescription.  
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 “Now they come to us and then we can’t change a prescription, because that is why I feel that 
the responsibility lies with the doctor…”- PP4 
This contrasted starkly with the role of the pharmacist as reported by the intern pharmacist. The 
intern pharmacist believed that the role of the pharmacist should include identification of ADRs. 
“Basically it is to identify or being able to identify ADRs. And then also its cause, and taking into 
account which different medications could have caused it...”- PP8 
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4.2.3. The responsibility of other healthcare workers 
 
Although pharmacists mentioned that they play a key role in the reporting process, they 
remarked that other healthcare cadres should also take responsibility for contributing to the 
reporting of ADRs. Various comments were made about the role medical officers and nursing 
staff play and how they contribute to the reporting process and the barriers that they experience. 
Most pharmacists indicated that it is a shared responsibility although the roles between the 
healthcare professionals differed. 
“Ok, the responsibility is with everybody, I think so...” -PP2 
The relationship and communication between the pharmacist and medical officers and nursing 
staff became evident through their comments. Some pharmacists mentioned that medical officers 
might be in a better position than pharmacists to report on ADRs because their consultation 
rooms are more private compared to the hatch at the pharmacy where the pharmacists have their 
interactions with the patients. On the other hand, some pharmacists had the view that medical 
officers are perceived as being very busy and that they do not have the time to report on ADRs. 
“No, what could maybe put the doctors off is that it might be time consuming to fill in the form, 
they are very busy and must see a lot of patients, and then they still have to fill in an ADR…”- 
SP2 
Some pharmacists indicated that medical officers and nurses reported more ADRs than 
pharmacists.  Although they reported more it was the view of some of the pharmacists, that 
medical officers were not always sure what to report on. They tended not to report common 
ADRs. 
“So stuff like that must be conveyed to the doctors that it is not only the serious reactions that 
need to be reported but the more common and minor reactions must be reported too.” – SP5 
Some pharmacists also indicated that medical officers might be quicker to connect a certain ADR 
with a specific medication compared to pharmacists. 
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“I think, and this might be only my perception, but that the pharmacy might be more careful to 
say that a certain medication is the cause of an ADR, whereas a doctor would be quicker to say 
it is because of a medication, they are quick to put the fault at the medication’s door. - SP6   
 Some pharmacists indicated that they had good cooperation with the medical officers. In some 
cases, the communication between the pharmacy staff and medical officers and nursing staff 
could be improved upon. 
“Yes, we have good cooperation and for the last two years, we have created more awareness, we 
have started through our PTC to give feedback.” – SP6 
 “Doctors have more time and it is more private, patients would not be so open, if they can talk 
to the doctor behind closed doors.”-SP4 
Interestingly, some pharmacists indicated that the responsibility depended on which healthcare 
professional the patient saw in the healthcare delivery chain and who the patient informed about 
the ADR experienced. One pharmacist indicated that the responsibility depended on who the 
patient informed. Another pharmacist indicated that the responsibility lies with the pharmacist 
because it is the pharmacist who sees the patient last. Patients that came back monthly to collect 
their medication would see the pharmacist and not the other healthcare professionals The 
pharmacist may therefore be responsible to report any ADRs that the patient might complain of.    
“Well it is because you are basically the last person the patient sees and you have a 
responsibility if they come back to you because they might only experience the reaction in a 
month’s time, when they collect their second prescription.” -PP8  
Some pharmacists indicated that patients are sometimes afraid to consult the doctor or the 
pharmacist. 
“I would think that the patient would complain first at the doctor. They complain at the 
pharmacy too, sometimes we find that they are afraid of the doctors, so they would rather come 
to the pharmacy and talk to the pharmacy staff.” – SP3 
It is evident that a complex relationship exists between the pharmacists and medical officers and 
nursing staff. Pharmacists refer patients back to the doctor for various reasons linked to the 
 
 
 
 
33 
 
reporting process and this action forms part of the role of the pharmacist as facilitator of the 
ADR reporting process in an attempt to decrease under reporting. This will be explored in more 
detail later in this section. Time constraints and work load pressures of the pharmacist serve as 
another motivator for the pharmacist to refer the patients back to the doctor. The pharmacist is 
thus involved in the identification of a potential ADR reporting opportunity compared to the 
actual reporting of ADRs.   
4.3. Importance of reporting 
 
4.3.1. Pharmacists view ADR reporting as important 
 
All pharmacists confirmed that the reporting of ADRs is an important process. The reasons 
include that it is in the interest of the patient’s safety, it has an impact on guidelines and policy, it 
is part of their role in surveillance with regards to medicine safety and that serious reactions can 
lead to the death of patients. 
 “…look it is important, the main function is to make it as safe for the patients as possible. There 
are different reasons for ADRs to take place.”- PP6 
“If it has a significant impact on the quality of life of the patient. ”- SP4 
“Yes. Yes, of course it is important because I think sometimes we take for granted, the drug has 
been available for a long time and surely, everybody knows about the ADR events, but no one 
actually reports it, so it is important that you do.” – SP1 
4.3.2. ADR reporting can contribute to patients’ safety 
 
One pharmacist indicated that it is important to record ADRs to stop problematic medication and 
replace it with safer medication. In order for this to happen there should be substantial reporting 
of a specific problematic drug. An example that was given was enalapril, an anti-hypertension 
medication which causes coughing as a side-effect and affects a large number of people.  One 
pharmacist indicated that ADR reporting was part of setting up a safety profile of the product and 
that it could even affect the scheduling of the product.  The intern pharmacist indicated that it is 
important to report in order to assess the risk: benefit ratio of the medication. Some pharmacists 
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believe that if a medication is found to be responsible for a large number of ADRs, it could lead 
to its withdrawal from the market.  
“Yes, it is very important. Like I said before, if everyone reported it , then the drugs that give a 
lot of problems, the frequency of the ADRs of a specific drug , will be noticed  if everyone reports 
on it, but if everyone does not report on it then,  then it will slip through.” –SP5 
“…if you get a drug reaction with one drug, then you can remove that drug, and substitute it 
with a more modern drug, that has fewer drug reactions and fewer effects of people".”- PP1 
“Yes, basically what are the chances of the medication causing more harm than good, so you 
have to keep track of that, because it can be withdrawn from the market if it causes a lot of 
adverse reactions.”- PP8  
4.4. Familiarity of the ADR reporting process 
4.4.1. Understanding the reporting process 
 
 Most supervisor pharmacists could describe how the reporting process works and could indicate 
what role they play in the reporting chain. Most indicated that they were involved in the collation 
of the reporting forms which were then submitted to the district office. From there the forms 
were forwarded to the Medicine Information Centre (MIC) and Medicine Control Council 
(MCC). The key stakeholders confirmed that a circular and posters were recently issued by the 
Department of Health that aimed to explain the reporting process.  
Production pharmacists were not always sure about how the reporting process worked in their 
area. One pharmacist indicated that at their facility reporting forms were sent to the sub district 
office whereas at other facilities the reporting forms were sent to the pharmacy which forward 
the forms to the district office. Uncertainty was also expressed with regards to where the forms 
were sent after being collated by the pharmacy. One pharmacist indicated that she had never 
received a reference number in five years of reporting ADRs. Most production pharmacists 
indicated that the reporting forms are collated by the supervisor pharmacist. Knowledge of the 
reporting process seemed more elementary amongst the production pharmacists compared to the 
supervisor pharmacists. The community service pharmacist and the intern pharmacist had a good 
understanding of the reporting process compared to other production pharmacists.  
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“There is an ADR form, that is filled in, and that is sent to, I am not sure who it is sent to, but all 
the ADRs are sent to a central person or whatever.”- PP2  
“So from last year it is sent to the district office, pharmaceutical services, so they get the whole 
district’s ADRs and then they know what is happening in the district, so they can also push it 
from their side.” –SP5 
4.4.2. Reporting as a continuous reporting process 
 
Some pharmacists indicated that most of the time reporting is an on-going process and reports 
are submitted as soon as they are received. One pharmacist indicated that it is arguably better to 
collate all the forms and send them away at the end of the month although serious reactions need 
to be reported immediately. One pharmacist indicated that continuous reporting depended on 
how busy the pharmacy is. When the pharmacy is very busy it is sometimes easier to make a 
note of the ADR in the folder and only report it at a later time. 
“I think it is an on-going process but it would be much better to send everything at the end of the 
month together, but a very serious drug reaction, something that can affect the liver or the 
kidneys, then it must be reported immediately in order to take it off the shelf.”-PP1 
4.5. Under-reporting of ADRs 
 
The study revealed that under-reporting amongst healthcare practitioners does take place. It was 
reported that common ADRs are often under-reported. Furthermore, identification of ADRs was 
not always found to be straightforward which also contributes to the phenomenon of under-
reporting. It was evident from pharmacists’ comments that they do play a role in decreasing the 
under-reporting of other healthcare workers. Some pharmacists noted that although under-
reporting does take place in practice, cases where healthcare workers sometimes over-report are 
also possible. A key stakeholder reported that some specialists target reporting certain 
medications in order to raise question marks about their safety in the hope of them being 
removed from the list of medicines available in the province. 
“…at that one meeting they mentioned that they would like the second generation anti-
psychotics, so they said well then we should report on the side effects of the first generation anti-
psychotics. So is there suddenly going to be a spike, then people will think oops!”-K1 
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4.5.1. Under-reporting of common ADRs 
 
Most pharmacists indicated that common and known ADRs should be routinely reported. One 
pharmacist indicated that it remains important to continue reporting ADRs even if it they are 
commonly reported. Another pharmacist indicated that ADRs become more common as the 
years go by thus it is important to identify ADRs in the first couple of years of a medication’s 
launch. Some pharmacists remarked that common ADRs are not recorded as they should be. 
They reported that medical officers might not report on common ADRs. 
The doctors do not always have a good perception of what to report…”-SP4 
“Well the most common one’s that you see regularly, for example the enalapril one that people 
do not record anymore"…”- SP1 
 “I think it is important to report common and uncommon reports...does not matter what 
reactions, all reactions must be reported so that is important yes.”-PP1 
 Common ADRs might be easier to record but some healthcare professionals fail to see the 
importance of recording these common ADRs. If the suspected ADR is already included in a 
package insert then healthcare workers might be reluctant to report it.  
 Some pharmacists had the opinion that rare ADRs might be easier to identify. One pharmacist 
indicated that severe ADRs would be dealt with promptly. The pharmacist reported that the very 
severe cases might not be seen in the primary healthcare clinics but in provincial hospitals.  
So sometime I feel that some of these reactions are severe enough to report or you get it so many 
times for the same drug for different patients but I myself as a pharmacist feel that I must fill out 
a ADR form, for every or all the reactions and not only for the ones that is stipulated on the 
patient information leaflet.” – SP7 
One pharmacist mentioned a circular that was issued by the Department of Health that 
recommends that only reactions that are not known or listed on the package insert should be 
reported. This differs from the common view held by most pharmacists that everything should be 
reported. 
 
 
 
 
37 
 
“The doctors do not always have a good perception of what to report, lots of times, there is this 
one drug that causes people to cough a lot, then they say it is so common, why must we report, 
everyone knows about it, why must we report, it is just another form that must be filled in..”.-SP3 
One key stakeholder stated that healthcare workers are not always sure when to report ADRs. 
Common ADRs are not reported but the unusual and more interesting ADRs are more readily 
reported.  Under-reporting of common ADRs thus occurs because healthcare workers are not 
sure if they should report on those reactions.  
“Ya, I think what makes it also difficult is they do not know when they should report an ADR, it 
is a common thing they tend to not report it, if it is unusual they will report it, if it is something  
interesting then they will report it, but I think in most cases ADRS are not reported because I 
think healthcare workers are unsure when to report and when not to.” -K1 
One key stakeholder was of the opinion that ADRs associated with new medication on the 
market and unexpected and serious reactions should be reported, rather than minor and common 
ADRs. The stakeholder mentioned that the Medicine Information Centre (MIC) has developed a 
poster with information about what should be reported.   
“I don’t think people should be reporting absolutely everything. They should be selective.” –K2 
One pharmacist indicated that ADR reporting might not be seen as a priority and has to compete 
with other work processes. Under-reporting might also be due to ADRs that are seen as not 
serious enough to report. A key stakeholder confirmed this by saying that ADR reporting is not 
considered important enough due to the fact that no-one acts on it unless there is a major 
consequence. There is no immediate response to an ADR report. Clinicians do not report as they 
should because they do not get feedback.  
4.5.2. Difficulty in identifying ADRs 
 
Some pharmacists reported on the difficulty in distinguishing between a side-effect, ADRs and 
allergic reactions which the patient may experience.  One of the pharmacists argued that there is 
a need to define properly what an ADR really is. 
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“…but if you get an ADR I think it is more something that is not known as a side-effect, and that 
is actually more serious, that is my perception, there is a very vague line between the two.” - 
PP2 
 Common ADRs can be easier to identify compared to more complex ADRs.  
“…for example the enalapril, you know what to look for, it is easy to identify but with more 
complex stuff if you are not sure if it is the disease, then it is a bit a difficult.”- PP8  
Some pharmacists had the opinion that other factors could be the reason for the perceived effect 
experienced and not the medication, such as the underlying disease of the patients. Although 
some pharmacists reported that those ADRs they can identify from the medical officer’s notes in 
the patient file they tend to report. One pharmacist however did indicate that one could still 
struggle to pick up the ADR from the medical officer’s notes. This was because it is sometimes 
difficult to distinguish between an ADR and the patient’s disease. This could also mean that in 
some cases an ADR could only be picked up from the doctor’s notes months after the 
occurrence, resulting in a delayed report. 
 Natural remedies and food could also potentially cause a reaction that could be mistakenly 
linked to a medication. 
“…there are so many factors, you can’t always say it is that…maybe the patient took it with 
something else, something at home that was not even prescribed, a lot of patients use natural 
remedies.”- PP6 
“There are listed side effects...you have to get a ‘nose’ for it, it is very unscientific, if the patient 
really complains about it and it is a bit over the top then you would send him/her to the doctor to 
check and ask if it is a side effect or not…”-SP3 
 “...it is not necessarily that that medication gave you the reaction, you might blame the 
medication for something that you experience…”- SP6 
Most pharmacists felt unsure about the identification of ADRs in the field. This insecurity about 
what could be the possible cause of an ADR led to the practice of referring patients back to the 
medical officer in order to gain clarity about the identification of the ADR and their possible 
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causes.  
 
“But the way I see it you cannot pinpoint something that you only see, that is just speculation, 
you have to send the patient back to the doctor to do the tests, and then the final report is just 
passed on…” -PP7 
 
The study revealed that pharmacists associated an ADR with an intervention that must take place 
with regards to the therapy of the patient. This could include changing the dose of the 
medication, stopping the suspected medication and/or prescribing another medication. One 
pharmacist indicated that the medical officers might just lower the dosage of a medication 
suspected of causing an ADR, in response to an ADR experienced. This adds to the motivation 
for referring patients to the medical officer in order to address the required therapeutic 
intervention. Not only are patients referred to the medical officer to make sure about the cause of 
the suspected ADR, but also to amend the therapy of the patient in response to the ADR 
experienced. One pharmacist indicated that most of the time it is the medical officer’s decision 
whether it is an ADR or not.  
“Usually they would stop the medication if they feel that it is giving them a problem usually they 
stop the medication, so did it improve after stopping the medication?” - PP6 
“…the patient went to the doctor and the doctor said it could be one of these three medications, 
the dose was changed (amlodipine one two times a day) and it still did not solve the problem, the 
doctor actually wrote a long what-to-do for the next three months so whoever the patient came to 
see ok next month try maybe this…”- PP3 
Some pharmacists reported that the long list of medication that patients sometimes take add to 
the complexity of identifying which medication might be responsible for the ADR. 
 “…so it is a lot of medications that patients are on, and you cannot always identify what 
medications caused it...because they use so much medications at the same time...”-SP4 
One key stakeholder indicated that public sector pharmacists should just report on any 
medications they suspect and should not spend time trying to pin-point which medication is 
responsible. It was the key stakeholder’s view that the identification of ADRs should be left to 
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the MIC.  Public sector pharmacists do not have the resources to routinely identify which 
medications could be responsible for the suspected ADRs. The key stakeholder reported that it 
sometimes takes the MIC more than two hours to find out which medication is responsible.  
4.5.3. Over reporting of ADRs 
 
Although most pharmacists indicated that under-reporting occurs, some have, however, alluded 
to instances where over-reporting might also take place. One pharmacist indicated that pharmacy 
staff is more likely to report a medicine that was not liked. A key stakeholder confirmed that 
clinicians might try to get rid of an unwanted medication through reporting suspected ADRs 
caused by the drug.  
“… at that one meeting they mentioned that they would like the second generation anti-
psychotics so they said well then we should report on the side-effects of the first generation anti-
psychotics. So is there suddenly going to be a spike in then people will think oops!” -K1 
Another pharmacist indicated that more reports were usually submitted from nursing staff during 
a vaccination campaign. This can be attributed to nursing staff being sensitised in training 
workshops before the scheduled vaccine campaign to be on the look-out for any reaction.  
One pharmacist asked whether an over-expectation existed with regards to ADRs reported. 
Another pharmacist indicated however that ADR reporting is a very uncommon process that one 
might see every six months.   
“Then I just want to add, sometimes there is too huge an expectation of ADRs then there would 
really be out there, they expect 2000 ADRs to be reported but in reality there might only be 
300.” -SP3 
Another pharmacist however indicated that medical officers seemed to have an incentive to 
report although the pharmacist was not entirely sure what it could be. One possible reason 
offered was that medical officers had access to otherwise restricted medication after the report 
had been completed. 
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“The doctors like I said to you are now a lot more willing to fill in the forms. And I think their 
motivation is that they can prescribe things like second line drugs, because they have filled in a 
motivation, so there is an incentive there for them to do it.”- PP4 
4.6. Perceived barriers 
 
Pharmacists identified barriers that made it difficult to partake in ADR reporting. Various 
barriers were mentioned including no privacy at the hatch when counselling patients, time 
constraints, workload pressure, lack of feedback, the long list of chronic medications that 
patients are on, limited contact time with patients, issues surrounding the reporting form, poor 
communication between healthcare workers and language barriers between the pharmacists and 
the patients. 
The main barriers experienced by most of the pharmacists are a lack of feedback, issues 
surrounding the reporting form and workload pressures and time constraints. 
4.6.1. Lack of feedback 
 
Most pharmacists remarked that they did not receive feedback on reports submitted. One 
pharmacist added to this by saying that no feedback is provided on what was done to rectify 
problems caused by ADRs. 
Some pharmacists however did receive feedback. Feedback provided included the district office 
providing feedback every quarter on the number of ADRs that were reported, feedback being 
provided at the District PTC and feedback received from the provincial HAST department on the 
number of ADRs caused by ARV medications. Three pharmacists indicated that they do provide 
feedback to their prescribers. Two pharmacists mentioned that they provide feedback at their 
local PTC meeting. One pharmacist lamented that the MCC should provide better feedback but 
did however acknowledge that the MCC does from time to time send medicine information 
warning letters to medical officers and pharmacists. The intern pharmacist indicated that they did 
not receive any feedback on the forms submitted and there was uncertainty whether the 
authorities received the reports.  
The type of feedback that some pharmacists would want to receive ranged from basic 
information such as common ADRs that were reported, to more comprehensive information such 
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as the consequences of the ADRs reported.  Pharmacists regarded receiving feedback as an early 
warning about medication that could potentially be problematic. Pharmacists need to have access 
to the information in order to counsel patients better.  
One pharmacist indicated that feedback is seen as a sign that the reporting of ADRs is not 
considered to be a waste of time. Improving the feedback provided to HCPs would also help in 
promoting ADR reporting amongst them. Another pharmacist and one key stakeholder indicated 
that reporting of ADRs, seen in the absence of feedback, is actually surprising. 
 “…and feedback, that is also done in the correct manner, that people does not feel that yes, I 
report but people does not do anything about it, so what…” - SP5 
 “It is easy to fill in a form but if do not get a response then people are going to lose interest…”-
SP2 
A key stakeholder mentioned that there are various viewpoints as to what constitutes feedback 
and whether it is deemed adequate by the person reporting the ADR. According to this 
stakeholder, lack of feedback should not be offered as an excuse for under-reporting and a “Dear 
Doctor” letter (medicine warning letter) should be acknowledged by HCPs as a form of 
feedback. 
 “My thing is that when you get a “Dear Doctor” letter, that is because of an ADR. And that is 
the feedback.”- K1 
Another key stakeholder indicated that HCPs required immediate feedback and that the “Dear 
Doctor” letter might reach HCPs too late to be considered adequate feedback. 
“But is almost too late feedback to me that. People should know about it before you get that dear 
doctor’s letter.”- K2 
4.6.2. Issues surrounding the reporting process 
 
Barriers in this category are associated with the reporting system itself that is perceived as being 
too complicated, the complexity of the reporting form, the availability of the reporting form and 
the awareness and understanding of the reporting process. 
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There were conflicting reports on the complexity of the reporting process. Some pharmacists 
indicated that the reporting process was easy and simplistic while others indicated that the 
reporting process was too complicated and acts as a barrier.  One pharmacist reported that the 
reporting process differs between facilities while another indicated that the reporting pathway is 
too long. They expressed a need for the reporting process to be standardised and be made more 
simplistic. 
Most pharmacists indicated that the availability of the reporting forms is not a problem and that 
HCPs should have adequate access to the reporting form.  Most healthcare workers would obtain 
master copies from their local pharmacy either electronically or in hard copy format.  Some 
pharmacists mentioned that a master reporting form can also be found in the South African 
Medicine Formulary, implying that it should be readily available.  
 Some pharmacists expressed a need for the reporting form to be standardised. They indicated 
that different forms exist for ARV and TB medications, other medications and vaccines.  
 “I know you get different forms for vaccines, ARV’s and normal adverse drug reactions.”-PP3 
There were conflicting reports on the time taken to complete the reporting forms and the 
complexity of the forms.  Some pharmacists indicated that the reporting is easy and simplistic 
and it takes very little time to complete the form. Other pharmacists reported the opposite, 
indicating that the form requires information that is not always available to them and that the 
form is complex and takes considerable time to complete. Some pharmacists indicated that they 
struggle with the section that requires that sequelae of the suspected ADR be recorded because 
this information is not always available to the healthcare workers.  One pharmacist indicated that 
there is limited space on the reporting form to record all suspected medication. The pharmacists 
mentioned that not all medications can be recorded in some cases. 
“…because some of those questions about the consequences, it is more clinical, that the 
pharmacy staff might not know, and if we can’t get the information from the notes then, we don’t 
always have the information to help us fill it in…”- SP6 
One of the pharmacists indicated that the reporting form was recently updated which makes it 
easier to complete.  The stakeholder confirmed that the Medicine Information Centre consulted 
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role-players when they designed the new form. Tick boxes were added to make it easier to 
complete. The key stakeholder confirmed however that pharmacists might not always have 
access to all the information needed to complete the reporting form. 
The pharmacist indicated that sometimes the fax lines to NADMC were busy while trying to 
submit the report. 
“All the doctors have with them Adverse Drug Reaction forms and it really is very quick, you just 
stick on a label, you just write all the...it is not a long form or anything.” –PP3 
4.6.3. Workload as a barrier 
 
Most pharmacists indicated that time constraints and workload pressures make it difficult to 
report ADRs.  In the busy state setup, healthcare workers are faced with different priorities and 
reporting of ADRs has to compete with other working priorities. Pharmacists indicated that 
medical officers and nursing staff have other forms to complete and ADR reporting adds to the 
paperwork burden. As reported earlier, some pharmacists see the reporting form as difficult to 
complete and takes time to complete. One pharmacist indicated that although reporting is 
straightforward they tend to neglect it whenever they are busy and have to work overtime. 
Some pharmacists however indicated that workload pressures is not really a contributing factor 
to under-reporting as reporting is a straight forward process. Both stakeholders confirmed that 
workload pressures and time constraints are barriers that prevent healthcare workers from 
reporting as they should. 
“Sometimes I can’t really be sure that it is an ADR, but I fill in the form anyway, I decide if it is 
an ADR or not, but time is a factor...”-SP6 
“I think if you take the doctors working in the hospital, its time because they need time to fill out 
the form, and they need the right information like all the medication that the patients were 
taking...”-SP7 
“...I know it is only one form but I have 100 patients needs  that I have  to attend to...I know it 
only takes a 20 – 30 minutes, but in that amount of time I can do a lot of other things...”-PP1 
 
 
 
 
45 
 
“So that is the biggest problem, lack of staff, it is not because of not wanting to, it is about 
prioritizing, it’s a huge thing…”PP5 
“Huge role, huge role. I think it is the workload.”- K1 
“I just feel that they do not have the time to do it, they just want to get through the patients...if it 
comes to 16h00, people just go home...they are not in the mood for such things.” PP7 
4.6.4. Lack of privacy 
 
Two pharmacists mentioned a lack of privacy at the dispensing hatch as a barrier, when 
counselling patients, compared to medical officers who usually see patients in consultation 
rooms. One pharmacist alluded to the fact that patients might be more inclined to disclose to the 
medical officer whether they had experienced an ADR because of the private setting compared to 
the pharmacy. 
 “...because at the hatch there is no real privacy for the patient, but in this pharmacy they are 
busy renovating…”- SP2 
“Doctors have more time and it is more private, patients would not be so open, if they can talk to 
the doctor behind closed doors…” -SP4 
4.6.5. Limited contact with patients 
 
A hospital pharmacist mentioned the lack of contact with patients due to the majority of their 
workload consisting of in-patient dispensing.  
 “But here by us we do not have direct communication with the patient.  So the doctor or the 
sister will report, here by us the doctor would report more, and we send it away.”- SP5 
4.6.6. Language barriers 
 
One pharmacist indicated that patients speaking a different language might make reporting a 
problem.  
“I can’t speak Xhosa, sometimes the patient would tell you in Xhosa what the problem is, 
everybody in the pharmacy might not know how important that is and what it is.”- PP3 
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“I think sometimes we have English speaking doctors here, and our community is Afrikaans 
speaking, this might be a barrier too…”-SP4 
4.7. Facilitation measures 
 
Various methods to aid the reporting process were mentioned by the pharmacists. These include 
the use of technology and electronic reporting, creating awareness through dedicated workshops 
and through PTCs, visual aids like posters, continuous training, and more staff to reduce the 
workload, the use of an acknowledgement letter after reporting and better feedback. 
4.7.1. Creating awareness 
 
Some pharmacists indicated that better awareness is needed amongst healthcare workers and 
patients to improve the reporting process. Improved awareness can be brought about through 
discussions at the PTC meeting, training workshops and the use of visual aids such as posters. 
Posters can sensitise patients about the existence of ADRs and inform healthcare workers on how 
the reporting process works. One pharmacist mentioned that new staff members should be 
informed about the reporting process and that supervisor pharmacists should encourage their 
staff to report more, especially pharmacist’s assistants. Although pharmacist’s assistants might 
feel out of their depth when it comes to ADR reporting, through encouragement and mentoring 
however, they can contribute to the reporting process.   
A key stakeholder confirmed that increased awareness can be created by putting up posters to 
remind people to report ADRs and through discussions at PTC level. The key respondent 
continued to say that pharmacists should be informed to look in the folders of patients and scan 
for suspected ADRs experienced by the patient. 
The other key stakeholder mentioned that there should be a reporting form in every folder to 
serve as a reminder to people to report ADRs. 
“...if there were visual aids like a poster to help show what a drug report is, put up the poster, 
they would walk everyday alongside the poster, and they would get to know the process, the 
poster needs to show the process that must be followed,   so it must just get easier, and the 
contact numbers must also be on the poster.”- PP1 
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 “We just keep on informing the doctors about the importance thereof, at meetings, or on a 
personal level, doctors are not always aware of the form, we ask if they have enough forms, if we 
must give them more forms…”-SP4 
“No I feel everybody is aware of how to do it... a lot of emphasis have been put on it...everyone is 
informed about it, at PTC level it is mentioned regularly”-PP6 
4.7.2. Facilitation of the reporting process 
 
Some pharmacists indicated that the reporting form should be made more available and that the 
reporting form needs to be simplified. One pharmacist made the recommendation to allow the 
doctor and the pharmacist to complete two halves of the form. 
“The form must be made available as much as possible.”- PP6 
“…maybe there should be a thing introduced where the doctor would say half fill out a form to 
report an ADR” – PP2 
A key stakeholder reported that ADR reporting forms must be made more accessible. The key 
stakeholder continued to say that the reporting form was recently updated and made easier to 
complete.  The stakeholder did however mention that the reporting form could be made even 
simpler and streamlined by removing the product complaint section of the reporting template. 
 “I mean we try to get a lot of input when we designed it and we tried to keep on updating it and 
we only added the TB drugs quite recently and the tick boxes for the TB drugs. But there is sort 
of essential information that we have to have.”- K2 
4.7.3. Improving feedback 
 
Improved feedback was mentioned by some pharmacists as a necessity for improving reporting 
of ADRs. One pharmacist commented on the type of feedback that needs to be improved. The 
suggestion was that the feedback includes the percentage of ADRs caused by a specific 
medication. One pharmacist proposed that at a when a certain percentage of patients experience 
ADRs for a particular medication then that medication should be deemed undesirable and be 
removed from being available to the public. One pharmacist indicated that better feedback can be 
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provided to prescribers at the PTC meeting. Another pharmacist indicated that an 
acknowledgment letter would be accepted as feedback. 
The stakeholders confirmed that feedback is an area that needs improvement. Improved feedback 
will increase reporting by creating awareness that will keep the reporting process alive.  
“Yes, an acknowledgement letter, yes, yes…”-SP4 
“…but what I think will change reporting is that they are given feedback which will keep them 
aware of the problem , or keep them aware that they have to report, keeping the awareness alive, 
so the feedback will maybe cause it to increase.”- S1 
4.7.4. Electronic reporting  
 
Some pharmacists indicated that electronic reporting might be the answer in improving the 
reporting process. One of these pharmacists questioned however whether it would be better than 
the current paper-based reporting process. She argued that ADR reporting should rather be made 
part of general work processes. Electronic aids like smart-phone applications can also assist 
pharmacists in providing the necessary information that can facilitate the reporting process. 
A key stakeholder confirmed that electronic reporting could make it easier to report but 
wondered whether the necessary electronic infrastructure such as an adequate number of 
computers at facilities is in place. 
“That is a difficult answer...maybe incorporate technology...we are still very paper based.” – 
SP1 
“I am not sure if an electronic system where you get immediate feedback, if you click then it 
would say there has already been reported 100 today, I don’t know and I have doubt that if we 
don’t do it on paper then we will not do it on a computer, I am not sure, but if it can become 
more part of the work process then it might make it easier…”-SP6 
“…it is impossible to know every single ADR. We need smart phones and APPs that goes with 
smart phones because if you are not going to get it computerised we need something that is 
accessible to us.”-PP5 
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“I think it would be really nice to have a computer with your patients’ details on to be able to 
click on a box that says Adverse Drug Event.”-S2 
4.7.5. Other facilitation measures 
 
One pharmacist indicated that ADR reporting has already been incorporated into the 
performance evaluation of staff members. The pharmacist also mentioned providing recognition 
at the PTC to those healthcare workers that reported in the specific time-period. This created 
awareness amongst the medical officers as well as creating a competitive culture amongst the 
prescribers to aid the reporting of more ADRs. Another pharmacist remarked that a culture of 
reporting should be established if one would hope to improve the reporting of ADRs. One of the 
key stakeholders confirmed that reporting should become part of staff members’ performance 
evaluations and should be measurable, keeping staff members accountable to report ADRs.  
“There is not a culture...so they should develop a culture so that everybody see the importance of 
it and develop the importance of it, drug reaction reporting”- PP8 
Another pharmacist indicated that the working relationship between the doctors and the 
pharmacy should improve. It should also be clear whose responsibility it is to report ADRs 
between the doctors and pharmacist, another pharmacist remarked.  
One of the pharmacists confirmed that although the new pharmacovigilance circular issued will 
make the process clearer, it will not necessarily lead to better reporting. What is really needed is 
improved feedback to HCPs. Another key stakeholder indicated what really is needed to improve 
reporting is for reporters of ADRs to know that the reporting resulted in an action or outcome. 
The stakeholder felt that forced reporting, as seen in KwaZulu-Natal, is not the answer. 
4.8. Conclusion 
 
The findings of the study provide insight into the role, duties and responsibilities of the 
pharmacists in relation to the pharmacovigilance reporting system as well as the complex 
relationship that exists between pharmacists and other HCPs. Knowledge was also gained about 
the perceptions and experiences of pharmacists, the barriers they experienced and the measures 
they propose for improving the reporting process.  
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CHAPTER 5: DISCUSSION 
 
5.1. Introduction 
 
The study highlighted five major findings, which gives us an understanding of pharmacists’ 
perception of their roles and experiences of reporting ADRs in the Cape Winelands District.  
These will be discussed in this chapter.  Firstly, pharmacists acknowledge the importance of 
ADR reporting, but seldom report ADRs themselves. Secondly, pharmacists identify ADR 
reporting opportunities and enable other HCPs to report ADRs. Thirdly, pharmacists associate an 
ADR with a therapeutic or clinical intervention. Furthermore, pharmacists feel that common 
ADRs should be reported and not only serious or rare ADRs. Various means of facilitating the 
reporting of ADRs were recommended by pharmacists.  Lastly, pharmacists gave various reasons 
for the under-reporting of ADRs and the barriers experienced.  
 
5.2. Importance of ADR reporting 
 
Pharmacists in the study strongly acknowledged the importance of ADR reporting.  This could 
be attributed to pharmacists seeing themselves as the custodians of medication 
(Pharmcouncil.co.za , 2015). Pharmacists in the study associated the reporting of ADRs with 
medication safety and felt responsible for ensuring it. In spite of this acknowledgement of the 
importance of ADR reporting, pharmacists rarely reported an ADR themselves.  Pharmacists, 
like other HCPs, reported that they encountered ADRs in practice every day. Nevertheless they 
were reluctant to report ADRs.  This phenomenon of pharmacists acknowledging the importance 
of ADRs but not necessarily reporting them is consistent with international literature (Suyagh et 
al., 2015; Jose et al., 2014; Ahmad et al., 2013; Walji et al., 2011; Elkalmi et al., 2011, Green et 
al., 2001) 
 
According to Elkalmi et al. (2011), who carried out a qualitative study exploring barriers and 
facilitators amongst community pharmacists reporting ADRs in Malaysia, although pharmacists 
generally exhibited a positive attitude when it came to pharmacovigilance, the respondents in 
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that study rarely reported ADRs themselves. Similarly, Walji et al. (2011) conducted a 
qualitative study amongst community service pharmacists in Canada investigating the 
pharmacist’s responsibility in reporting natural health product related ADRs found that they 
seldom reported ADRs although they acknowledged that this falls in their scope of clinical 
responsibility and was important (Walji et al., 2011). In the South African context, Dheda (2013) 
reported on the implementation of a pilot patient centered decentralized pharmacovigilance 
system in Mpumalanga, South Africa. The training workshop that formed part of this programme  
revealed that all HCPs had encountered one or more ADRs before but fewer than half of those 
ADRs were reported (Dheda, 2013). 
 
Pharmacists’ acknowledgement of the importance of ADR reporting is not surprising, as most 
pharmacists universally feel responsible for medicine safety. This belief of being responsible for 
medicine safety is likely instilled early during the undergraduate studies.  However, it is not 
always clear what prevents pharmacists from reporting ADRs even though they regard it as 
important. Possible explanations for this phenomenon that have been put forward include 
barriers pharmacists experience in the workplace which make it difficult to report ADRs and 
issues related to a pharmacovigilance reporting system (Elkalmi et al., 2011; Walji et al., 2011; 
Green et al., 2001). Pharmacists’ beliefs that ADR reporting is important, paves the way for 
pharmacists  to play a significant role in any pharmacovigilance system, although there is a need 
to have a better understanding of the barriers pharmacists face in order to strengthen the 
pharmacovigilance system.  
 
5.3. Pharmacists identify ADR reporting opportunities and enable other HCPs to 
report ADRs 
 
The study revealed that pharmacists identify ADR reporting opportunities during their normal 
clinical work and enable other HCPs to confirm the occurrence of an ADR and report it.  
Pharmacists primarily identify ADRs when they scan patient folders for any clues that could 
indicate that an ADR had occurred. A pharmacist might only identify an ADR after a 
considerable time period while going through a patient’s folder which would lead to delayed 
reporting. An ADR reporting opportunity may be identified in various ways. Firstly, when the 
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pharmacist observes that the patient’s medication was changed, possibly in response to an ADR 
experienced by the patient. Secondly, when the pharmacist observes in the patient‘s file that the 
medical officer identified an ADR and recorded the details in the patient’s file without reporting 
the ADR. Thirdly, when the patient discloses to the pharmacist during the counselling session 
that he/she has possibly experienced an ADR. 
 
Some pharmacy staff directly report an ADR based on the information available in the patient’s 
folder. In most cases however, the patient is referred back to the medical officer to complete the 
ADR reporting template.  Pharmacists therefore help prevent the under reporting of ADRs by 
identifying missed ADR reporting opportunities and enabling other HCPs to report. 
Inappropriate ADR referrals, i.e. referrals that not linked to a possible ADR occurrence, could 
however add to the workload of medical officers. 
 
Not much has been reported in previous literature on the pharmacist’s role in identifying ADR 
reporting opportunities, although some research has pointed to the use of medical records as a 
source of identifying missed ADR reporting opportunities (Khan et al, 2015; Henriksson et al., 
2015). These researchers explored utilizing detailed electronic medical records to identify 
potential ADRs, either from electronic clinical notes made by medical officers or scrutinizing 
certain medications prescribed as antidotes to counter the effects of ADRs caused by other 
medication (Khan et al., 2015; Henriksson et al., 2015). Once implemented, such systems could 
be highly accurate in identifying missed ADRs with minimum costs compared to traditional 
methods (Khan et al., 2015).  The research confirms that clinical records and notes in patient 
files can indeed be used to identify missed ADR reporting opportunities. The difference shown 
by the research mentioned, compared with the finding in this study is that pharmacists manually 
evaluate medical records for signs of ADRs that could have occurred. The ability to identify 
ADR reporting opportunities from medical notes is thus based on the clinical expertise and 
experience of the pharmacists in the study. In the absence of an automatic identification system 
utilizing electronic patient records, pharmacists with the appropriate training could therefore 
assist in identifying ADR reporting opportunities and help reduce the under-reporting of ADRs. 
 
This finding tells us that pharmacists in the study were sensitized to ADR reporting and could 
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play an important role in preventing missed ADR reporting opportunities. This study provides 
detailed information on this point, which would be of value in future training sessions and could 
strengthen pharmacovigilance practices at primary healthcare level. Future training should thus 
concentrate on improving the quality of referrals back to medical officers and enabling 
pharmacists to have more confidence reporting ADRs directly from information available in 
patients’ files. 
 
5.4. Pharmacists associate an ADR with a therapeutic intervention 
 
Alongside the previous finding, some pharmacists in the study associated an ADR with a 
therapeutic or clinical intervention. In general, therapeutic interventions usually involved a 
clinical action more closely associated with medical officers and were viewed by pharmacists in 
the study as being outside their legal and clinical scope of practice. A clinical intervention could 
include a change of medication, change of dose, and other prescription changes or might involve 
the medical officer referring the patient to a higher level of care depending on the severity of the 
suspected ADR. A clinical intervention could include performing complex diagnostic tests, 
observations and laboratory investigations.  
 
A change in prescription of medication could be an action needed to reduce or prevent the 
suspected ADR. Performing diagnostic tests might be needed to help determine the cause of the 
ADR. A pharmacist is not allowed to conduct the above mentioned examples of clinical 
interventions as they fall outside their legal and clinical scope of practice in South Africa 
(Pharmcouncil.co.za, 2015). This finding compares well with Walji’s et al. (2011) study in which 
pharmacists also referred patients to medical officers even though they themselves identified the 
ADR. They had a similar view that the medical officers had a better clinical picture of the 
patient’s health status, including access to diagnostic tests, as well as better access to all the 
information required to complete the ADR report form (Walji et al., 2011). Mahmoud (2014) 
also reported that community pharmacists would advise patients presenting with an ADR at the 
pharmacy to consult a general practitioner for further management.  Although pharmacists in the 
study had similar views, the difference compared with Walji et al. (2011) was that pharmacists in 
this study believed that a therapeutic intervention needed to take place as a consequence of an 
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identified ADR. Patients could experience an underlying disease that could add to the complexity 
of determining the cause of the ADR.  Pharmacists could be afraid of submitting inappropriate 
reports that could be linked to insecurities in performing actions outside their scope of practice 
(Green et al., 2001).Pharmacists might be fearful of accepting professional liability and thus run 
the risk of being disciplined by superiors or fear of looking ludicrous  in reporting ADRs (Visacri 
et al, 2015; Aljadhey et al., 2014). Pharmacists association of an ADR experience with a clinical 
intervention is an important factor limiting their reporting of ADRs.  
 
The result of this belief of pharmacists is that patients are referred from the pharmacy back to 
medical officers for the clinical intervention. In this way, although pharmacists do not directly 
report an ADR, their referral to medical officers would help improve reporting of ADRs.  
This finding is consistent with the first finding as it offers an explanation why pharmacists, while 
they acknowledge the importance of ADR reporting, do not themselves necessarily report. 
Furthermore, although pharmacists identify ADR reporting opportunities during their routine 
work, they might not necessarily submit reports it as they associate an ADR with a possible 
therapeutic intervention that needs to take place in the interest of the patient.  
 
Although pharmacists in the study acknowledge their role as the drivers and gatekeepers of the 
reporting process, they acknowledged the responsibility of other HCPs to report ADRs. Walji et 
al. (2011) reported that pharmacists’ overlapping responsibility with other HCPs in terms of 
pharmacovigilance outcomes could contribute to under-reporting of ADRs, as shared 
responsibility may mean that no one takes responsibility to report. In this research, however, 
pharmacists appeared to complement medical officers by referring suspected ADRs for their 
management. It is thus important in any pharmacovigilance system to identify shared 
responsibility amongst HCPs but at the same time acknowledge the roles, skill sets and abilities 
of different HCPs to enable them to complement each other in strengthening the reporting 
process. It is evident from the study that a complex relationship exists between pharmacists and 
other members of the multidisciplinary team, particularly with medical officers and nursing staff. 
This relationship has implications for patient management as seen in the patient referrals from 
pharmacists to medical officers.  
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Although pharmacists in the study strongly identified being gatekeepers and drivers of the 
reporting process, they should not be limited to this role in ensuring medication safety as part of 
the multidisciplinary team. It is important to note that most ADRs are preventable and reversible 
through early identification, improving medicine use, reducing prescriber errors and prompt 
management of the ADR (Jose et al., 2014, Shamna et al., 2014; Khan et al., 2013; Mehta, 2011). 
Pharmacists can play a great role in improving medication safety as part of the multidisciplinary 
team by enforcing principles of Rational Medicine Use and through identification and feedback 
of prescribing errors. Pharmacists are also in an ideal position to affect patient behaviors through 
adherence counseling. Patients might exhibit behavior which could add to the risk of an ADR 
from the use of over-the counter medications, the use of natural health products, smoking and 
increased alcohol intake (Alomar, 2014; Shaw et al., 2012). Smoking and alcohol intake could 
have an effect on the metabolism of medication. Over-the-counter medication could interact with 
prescribed medication leading to increased risk of an ADR (Alomar, 2014). Certain categories of 
patients, such as the elderly, are more at risk of ADRs due to altered metabolism of medication 
and the potential of poly-pharmacy in such patients which requires a greater vigilance on the part 
of pharmacists (Alomar, 2014).  Pharmacist counseling of patients could help prevent ADRs 
through the correct use of medication by patients (Jose et al., 2014; Mehta, 2011).  
 
5.5. Pharmacists feel that common ADRs should be reported 
 
An unexpected and contrasting finding compared to previous research was the strong belief of 
some pharmacists in this study that common ADRs should be reported. Pharmacists believed that 
by reporting common ADRs en masse, authorities might decide to remove the problematic 
medication from the approved public sector formulary. This is in contrast to previous research 
where pharmacists either acknowledge that authorities only want novel or serious ADRs from 
newly marketed medication and believe that reporting well-known ADRs is a waste of time 
(Green et al., 2001). Green et al. (2001) reported that pharmacists in their study had the view that 
reporting minor ADRs would not really contribute to improved medicine safety. Although 
certain changes were made in the past to ARV guidelines after reports of serious ADRs, it is not 
clear if a problematic medication has been removed from the approved formulary because of the 
volume of ADR reports received. There is, however, local evidence that medication has been 
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added to the formulary as an option to counter the effects of a common ADR associated with a 
routinely prescribed medication. One of the most common ADRs to be reported is cough 
associated with the use of a hypertension medication called enalapril, which is classified as an 
essential medication. After numerous ADR reports losartan was added by the Provincial 
Pharmacy and  Therapeutics Committee (PPTC) to the approved formulary as an option for 
patients suffering from cough associated with enalapril. (See Appendix 9, page 102) 
 
The belief that an emphasis should be placed on the reporting of common ADRs is in contrast 
with previous research, which showed that pharmacists were reluctant to report clinically 
insignificant and well-known ADRs and were more motivated to report rare and serious ADRs 
(Elkalmi et al., 2011).  A provincial pharmacovigilance circular issued by the Western Cape 
Department of Health in 2013 advises HCPs to report serious, rare and novel ADRs only (see 
Appendix 5, page 86). Whilst pharmacists might find it easier to report common ADRs that are 
easy to identify and that probably do not require much clinical intervention, the question is: 
should valuable time be ‘wasted’ on the reporting of ADRs that are common and well reported in 
the past? The exception should be reporting common quality issues associated with new generic 
medication as inferior quality medication could have a significant impact on a patient’s 
therapeutic outcomes.  It has been suggested that in a resource-constrained environment greater 
emphasis should be placed on reporting ADRs associated with novel medication and rational 
medicine use interventions that could help prevent ADRs and other complications (Alomar, 
2014)  
 
5.6. Barriers to reporting ADRs 
 
Pharmacists reported that they faced several barriers in reporting ADRs. The main barriers  
mentioned were  a lack of adequate feedback, heavy workload and time constraints, uncertainty 
in identifying the cause of  an ADR and issues pharmacists had with the reporting process. These 
barriers have been mentioned by several researchers prior to this study (Elkalmi et al., 2011; 
Walji et al., 2011; Green et al., 2001).  
 
Heavy workload and time constraints are repeatedly mentioned in published literature as reasons 
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for under-reporting of ADRs. Heavy workload leads to other tasks being prioritized above 
pharmacovigilance activities, leading to under reporting. Completing another form is seen as 
adding to the already over-laden paperwork burden experienced by HCPs. Pharmacists had 
conflicting views on how quick it was to report an ADR and whether workload could be offered 
as an excuse to not report an ADR. A possible reason for this could be the difference in reporting 
common, easy ADRs, compared with ADRs that are more complicated. Completing a common, 
well-known ADR could be a relatively quick and easy task for most pharmacists. Time 
constraints and workload, however, remains a valid concern. To lessen the impact of this 
universal obstacle, managers should ensure that adequate continuous training and awareness are 
provided to all HCPs (Elkalmi et al., 2011). 
 
A lack of adequate feedback was the most common barrier to reporting ADRs mentioned by 
pharmacists in this study. Previous research has confirmed that appropriate feedback is essential 
in facilitating ADR reporting (Elkalmi et al., 2011). There was no common response as to what 
type of feedback pharmacists preferred. Interestingly the “Dear Doctor” letter or medicine 
warning document sent to all HCPs were not really regarded as a type of feedback by 
pharmacists in this study.  Due to lack of resources, the National Pharmacovigilance Centre 
(NPC) would not be able to provide individualized feedback for every ADR report (Dheda, 
2013). In the Western Cape Province, a quarterly provincial pharmacovigilance report detailing 
number of reports submitted, medication involved and type of ADRs reported is currently being 
provided by the Medicine Information Centre in conjunction with the Department of Health’s 
PPTC to all HCPs.  
 
Providing continuous feedback helps with creating awareness but does it aid in improving the 
management of ADR cases in especially primary healthcare settings? Dheda (2013) reported on 
the initial success of a decentralized pharmacovigilance system which consisted of 
multidisciplinary cluster-based teams. These teams received training on pharmacovigilance 
activities and relied on expertise within the team to help improve the management of ADR cases 
on the ground through monthly meetings (Dheda, 2013). The NPC would then provide guidance 
on trends observed from reports received by the multidisciplinary cluster-based teams. In future, 
as part of a multidisciplinary team, pharmacists would be called upon to provide statistical 
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feedback to team members as opposed to receiving individualized feedback from the NPC. 
 
Uncertainty in identifying the possible cause of an ADR and an accompanying lack of 
identification skills were reported by pharmacists in the study as a reason for under-reporting. 
Previous research confirmed this as a barrier contributing to under-reporting (Jose et al., 2014; 
Ruud et al., 2010; Suleman, 2010; Green et al., 2001). Furthermore, one pharmacist interestingly 
noted that the long list of chronic medications (sometimes in excess of seven items) that patients 
are on seems to complicate the process of identifying which medication is potentially responsible 
for the suspected ADR. Poly-pharmacy, where a patient is on a long list of medications, is 
widely recognized as a contributing factor in increasing the risk of an ADR (Alomar, 2014; Khan 
et al., 2013). Obviously, the more medication the patient is on, the greater the risk of an ADR 
experienced due to an increase risk of medication interactions (Alomar, 2014). Poly-pharmacy 
can also lead to prescribing cascades, meaning that other medications are prescribed to help 
reduce the adverse effects of medication already prescribed (Alomar, 2014). Pharmacists are not 
really in the position to ascertain which of the prescribed medication could be responsible for the 
suspected ADR due to a lack of available time, experience and reference resources. Nevertheless, 
pharmacists could play an important role in helping to prevent ADRs by promoting the principles 
of Rational Medicine Use, reducing prescriber made errors and improving adherence on chronic 
medication.    Rational Medicines Use requires that patients receive medications appropriate to 
their clinical needs, in doses that meet their own individual requirements, for an adequate period 
of time, and at the lowest cost to them and their community (WHO, 2016). 
 
The impact of this barrier could be mitigated by the use of an ADR causality assessment tool. 
ADR identification decision aids, such as the Naranjo, Yale and Karch algorithms have been 
developed in the past (Doherty, 2009).  Although the Naranjo algorithm is commonly used, no 
universal “Gold Standard” causality assessment tools have yet been developed (Doherty, 2009). 
A causality assessment algorithm which could identify the link between an ADR and a suspected 
medication, when applied to information available in electronic medical records, would be 
beneficial (Khan et al., 2015; Maitra et al., 2014). In our situation however, where electronic 
medical records have not been universally implemented, pharmacists could find benefit in a 
manual causality assessment tool that aims to remove some of the uncertainty in identifying the 
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possible cause of an ADR.  
 
Pharmacists had conflicting viewpoints on the user friendliness of the ADR reporting form. 
Some pharmacists mentioned that there were three different reporting forms – one for ART and 
TB medications, one for vaccines and one for other medicines. The study highlighted recent 
efforts made by the MIC to simplify the reporting template. This involved combining two 
previous forms used to report different medication and to decrease writing by adding tick boxes. 
A complicated reporting template could be viewed as a barrier to under-reporting.  
The user-friendliness of the reporting template should be taken into account with different types 
of ADRs that are reported. It is understandable that pharmacists may find it easier to complete 
the reporting template for common, well-known ADRs, requiring little supporting information 
than difficult unknown ADRs.  
 
Some pharmacists reported the part of the reporting form requiring information about sequelae 
as being problematic, as they would not have access to that information especially if the patient 
has been referred to another institution. Therefore, a reporting template requiring information 
pharmacists do not have ready access to might be viewed as difficult. It is important to note that 
reporting templates should be as user-friendly as possible for all HCPs. Not having access to all 
the required information should not deter pharmacists and other HCPs from reporting ADRs. 
However, members of the multidisciplinary team should be supported by each other to complete 
the reporting form as accurately as possible. 
 
In this study, pharmacists reported that the availability of the reporting form was not reported as 
being a barrier and they indicated that it was relatively easy for HCPs to obtain copies of the 
reporting from the pharmacy. Pharmacy staff could either fax blank forms or send forms 
electronically which could then be printed by HCPs. As pharmacy staff were primarily 
responsible for the distribution of the reporting form copies, it would be unlikely that 
pharmacists would raise the availability of the reporting form as a barrier or reason for under 
reporting. A future recommendation would be to make the availability of ADR forms part of the 
verification pharmaceutical audit conducted by pharmacy staff. The pharmaceutical verification 
audit is an inspection based on South African Pharmacy Council guidelines and aims to improve 
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pharmaceutical norms and standards (See Appendix 10, page 109). In the Western Cape, this 
audit is only conducted in the Cape Winelands and in a similar format in the Overberg District.  
When facilities are audited, clinic managers should be asked to display ADR reporting forms in 
the various consultation rooms. 
 
Pharmacists in the study had a varied understanding of the pharmacovigilance system. There was 
a marked difference in terms of knowledge about how the pharmacovigilance system works 
between supervisor pharmacists and production pharmacists. This could be attributed to 
supervisor pharmacists being more involved in attending meetings and having better access to 
communication, such as circulars, compared to production pharmacists. Supervisor pharmacists 
have more management tasks compared with production pharmacists and probably have a higher 
sense of being responsible as gatekeepers of the reporting process. Another research study has 
also reported on differences observed between different categories of pharmacists. Suyagh et al. 
(2015) reported on the difference in knowledge and awareness of the pharmacovigilance system 
observed between hospital and community pharmacists. Suyagh et al. (2015) speculated that the 
possible reason for this could be due to hospital pharmacists being more in contact with other 
HCPs and thus more exposed to scenarios where they have to give advice or support in the 
identification process of ADRs. In contrast to Suyagh’s et al. (2015) research study, all 
pharmacists in this study were part of an integrated district healthcare system with daily contact 
between district hospital and clinic-based pharmacists and other HCPs. In general there did not 
appear to be any difference between supervisor pharmacists based at district hospitals and those 
at clinics in terms of knowledge and awareness of the pharmacovigilance system.  Nevertheless, 
lack of knowledge about the pharmacovigilance system was not raised in this study as a barrier, 
which is in contrast with other research conducted. In the Suyagh et al. (2015) and Elkalmi et al. 
(2011) studies, poor knowledge amongst pharmacists about their pharmacovigilance system was 
found to be a great contributing factor for under-reporting of ADRs by pharmacists. 
 
5.7. Facilitation of ADR reporting 
 
Pharmacists suggested various means of facilitating ADR reporting including electronic 
reporting aids, creating increased awareness amongst healthcare professionals, conducting 
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continuous training and making amendments to the reporting form, which were in line with 
previous research conducted (Elkalmi et al., 2011; Walji et al., 2011;Green et al., 2001). Some 
pharmacists in the study mentioned providing continuous training sessions as a means to 
improve ADR reporting. This notion is well supported by previous research conducted (Elkalmi 
et al., 2011; Green et al., 2001). Green et al. (2001) reported that pharmacists who received 
training were more likely to report ADRs and had a better understanding of the 
pharmacovigilance system. Other research reported on a separate incentive to report ADRs as a 
means to facilitate reporting, either in favor or against it. This not only included financial 
incentives but other incentives such as receiving recognition or journal subscriptions (Elkalmi et 
al., 2011). 
 
Interestingly, receiving a financial incentive was not reported as a means to facilitate ADR 
reporting by pharmacists in this study. This could be due to pharmacists’ high sense of 
responsibility being the drivers and gatekeepers of the reporting process. It is important to note 
that providing a financial incentive could be a double-edged sword in facilitating ADR reporting 
in that a substantial incentive could increase minor ADR reporting with little benefit to 
medication safety, whereas if the incentive was small pharmacists might consider it not a 
worthwhile action (Elkalmi et al., 2011; Green et al., 2001).  
 
One recommendation mentioned by a pharmacist and key stakeholder was to make 
pharmacovigilance part of the performance management of pharmacy staff in the province. In 
this way performance management could provide an incentive to pharmacists who exceeded 
expectations in improving pharmacovigilance outcomes which would be beneficial in keeping all 
pharmacy staff accountable for improving ADR reporting. 
 
Creating continuous awareness is essential for ensuring that HCPs do not under report ADRs. 
The study highlighted various means of creating awareness of the reporting process, such as 
using the PTC, clinical morbidity and mortality meetings and other meetings with the medical 
officers where pharmacists could give feedback and provide additional information. Creating 
awareness as a means to increase ADR reports is in line with previous research (Green et al., 
2001). These recommendations mentioned by pharmacists in the study are significant in moving 
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towards a decentralized pharmacovigilance system as reported by Dheda (Dheda, 2013).  
 
The study found that respondents felt that the use of technology could help in enabling quicker 
and more accurate reporting of ADRs and provide a means to give specific feedback through 
electronic means.  Whilst the use of electronic reporting could offer advantages for more 
efficient reporting, it was mentioned that the technological infrastructure should first be created 
to facilitate electronic reporting. Previous research has mentioned electronic reporting as a means 
to help improve pharmacovigilance outcomes (Elkalmi et al., 2011).  It should be noted that 
Kenya has already implemented an electronic ADR reporting system that greatly improved the 
rate of reporting in that country (Otieno, 2013). The decentralized pharmacovigilance system in 
Mpumalanga Province could perhaps be a good setting to pilot a similar electronic system as 
seen in Kenya. 
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CHAPTER 6: CONCLUSION AND RECOMMENDATIONS 
 
6.1. Conclusion 
 
The findings of this study contribute to our understanding of the role of rural pharmacists in the 
public healthcare system in South Africa in supporting a spontaneous reporting 
pharmacovigilance system. Pharmacists’ positive acknowledgement of the importance of ADR 
reporting is significant in improving the pharmacovigilance system as they are willing to 
cooperate in improving it, especially in moving towards a decentralized pharmacovigilance 
system as proposed by Dheda (2013).  
 
Although pharmacists did not directly report ADRs they contributed to improve 
pharmacovigilance outcomes through identification of ADR reporting opportunities and reducing 
under-reporting by enabling and supporting other HCPs to report. Although this gatekeeper and 
supportive role pharmacists play is important, more work needs to be done to create awareness 
amongst pharmacists that improving medicine use outcomes and reducing prescribing errors will 
help prevent ADRs. 
  
The study highlighted two beliefs held by pharmacists which have implications for future efforts 
to improve or change the pharmacovigilance reporting system. Firstly, pharmacists’ belief that 
common ADRs should be reported was a contrasting finding to other research on this topic. 
Secondly, pharmacists’ association of ADRs with a therapeutic intervention was a novel finding 
compared with other research. This finding illustrates the complex relationship that exists 
between pharmacists and medical officers. 
 
The study illustrates reasons for under-reporting and barriers faced by pharmacists in reporting 
ADRs.  Future pharmacovigilance training for pharmacists is essential in reducing the negative 
impact of these barriers by improving pharmacovigilance knowledge and understanding amongst 
pharmacists. This would enable them to make better operational and clinical decisions, for 
example, improving pharmacists’ understanding of which medicine might be responsible for an 
ADR could lead to less time being wasted trying to identify which medication is responsible, 
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improving reporting rates and reducing inappropriate referrals to medical officers. In addition, 
pharmacists could play key roles as gatekeepers and drivers of pharmacovigilance reporting 
systems, enabling other HCPs to report ADRs by identifying ADR reporting opportunities, 
creating continuous reporting awareness and providing appropriate feedback as part of a future 
multidisciplinary decentralized pharmacovigilance team. 
 
6.2. Recommendations  
 
Several key recommendations are proposed: 
 
1. Future circulars, training workshops and awareness posters about the ADR reporting 
process should inform all HCPs to report any medication suspected of being the cause of 
an ADR and not waste time in trying to identify the medication that caused it. The 
message should be: If you suspect an ADR, report it.  
 
2.  Training workshops should be conducted with pharmacists to improve their skills in 
terms of identifying ADRs, how and what to report and the appropriate referral of 
patients to the medical officers. The training should also emphasize the link between 
improving rational medicine use outcomes, reducing prescribing errors and preventing 
the occurrence of ADRs. 
 
3. An annual assessment on the availability of reporting forms in all health facilities should 
be conducted. This assessment should include pharmacies and clinical consultation 
rooms. In addition, the MIC should conduct a survey on the user-friendliness of the 
reporting form and enable HCPs to provide recommendations to help improve the 
reporting form template. 
 
4. Pharmacovigilance should be a standing item on the agendas of sub-district PTC 
meetings at which supervisor pharmacists should give quarterly updates to sub-district 
management on ADRs reported. Promoting pharmacovigilance should be part of 
pharmacy staff job descriptions and performance agreements. Newly appointed HCPs 
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coming into the healthcare system, such as community service pharmacists, nurses and 
medical officers should be orientated and informed about the pharmacovigilance system 
in place. 
 
5. As this study focused primarily on the experiences and perceptions of pharmacists in the 
rural health district, a follow-up study should explore perceptions and knowledge of 
medical officers and nurses of ADR reporting, specifically on the availability and 
complexity of the reporting form. 
 
6. The MIC should explore the development of a basic ADR causality assessment tool that 
could assist pharmacists and other HCPs in identifying a possible ADR and improve 
confidence amongst pharmacists and HCPs in reporting ADRs. Such a tool would also 
aid in raising pharmacovigilance awareness amongst pharmacists and HCPs but would 
need to be linked with appropriate training before such a tool could be implemented.   
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Appendix 2: Cape Winelands District Population Figures 
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Appendix 3: Department of Health ARV ADR reporting form 
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Appendix 4: Provincial Pharmacovigilance Circular 2008 
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Appendix 5: Provincial Pharmacovigilance Circular 2013 
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Appendix 6: Data Collection Tools 
 
 
A. Demographic questions 
For each question mark only one response unless otherwise indicated. 
 
1. Gender  
Male  
 
 
Female  
 
2. Age  
                  years 
 
3. Race  
Asian 
 
Black 
 
Coloured 
 
Indian 
 
White 
 
Other                   Specify: 
 
Chose not to answer 
 
4. Mother 
tongue 
language 
 
 
Afrikaans 
 
English 
 
isiNdebele  
 
IsiXhosa 
 
isiZulu 
 
Sesotho 
 
Sesotho sa Leboa 
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Setswana 
 
siSwati  
 
Tsivenda  
 
Xitsonga 
 
Other                                              Specify: 
 
5. Education 
Mark response 
for both 5a) and 
5b) 
 
5a) Highest pharmacy qualification obtained 
 
Bachelors degree 
 
Masters degree 
 
Doctorate 
 
 
5b) Other post-graduate qualifications, if applicable 
 
Specify: 
 
Not applicable  
 
6. Employment 
Mark response 
for 6a) and 6b) 
 
6a) Number of years of practice as pharmacist                          years 
 
 
6b) Current position 
 
Pharmacy Manager 
 
 
Supervisor Pharmacist 
 
Production Pharmacist 
 
 
Community Service Pharmacist 
 
Intern Pharmacist 
 
Other             Specify: 
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6c) Previous experience (mark all that apply) 
 
Community Pharmacy 
 
Consultant Pharmacy  
 
Manufacturing Pharmacy  
 
Private Institutional Pharmacy  
 
Public Institutional Pharmacy  
 
Wholesale Pharmacy 
 
Provider of Education and Training 
 
Other            Specify: 
 
7. Adverse Drug 
Reaction 
reporting 
7a) At least one ADR reported in professional career? 
 
Yes 
 
No                     End of form 
 
 
7b) Estimated number of ADRs reported in professional career 
 
1 – 5 
 
5 – 10 
 
 >10 
 
7c) Date last ADR reported 
                          _    
 
           Month    –      Year  
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B. Pharmacist Semi-structured Interview Schedule 
1. What do you think is the pharmacist’s role in reporting ADRs ? 
Probe : Who’s responsibility? Part of pharmaceutical care role?  Can you identify an 
ADR ? Did you come across an ADR? How important is it to report an ADR ? Have you 
reported ADRs? 
2. Please describe the ADR reporting process in your District ? 
Probe : When should one report ? Where to one find ADR forms ? 
Do you ever receive feedback on the report that was submitted ? 
3. What are the barriers to reporting ADRs in this district? 
Probe: workload? Complexity of system? Feedback? 
4. What would facilitate increased reporting of ADRs in this district? 
 
C. Key Stakeholder Semi-structured Interview Schedule 
1. Please describe the ADR reporting process in the Western Cape Province? 
 
2. How easy is it to report an ADR in the public sector ? 
 
( the new circular that was issued recently, do you think that that will facilitate more 
reporting ? ) 
 
3. What would you say is the role of pharmacists in the reporting of ADRs ? 
 
4. What do you think is needed for pharmacists to report more ADRs ? 
 
( What would you say is more needed to report at facility level ? ) 
 
5. What would you say are the barriers  in reporting more ADRs ? 
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Appendix 7: Ethics Committee Approval Letter 
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Appendix 8: Participant Information Sheet 
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Appendix 9: Pharmaceutical Code List Supplementary List No. 131 
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Appendix 10: Cape Winelands District Pharmaceutical Verification Template 
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